WO2011112828A1 - Pde10 inhibitors and related compositions and methods - Google Patents
Pde10 inhibitors and related compositions and methods Download PDFInfo
- Publication number
- WO2011112828A1 WO2011112828A1 PCT/US2011/027927 US2011027927W WO2011112828A1 WO 2011112828 A1 WO2011112828 A1 WO 2011112828A1 US 2011027927 W US2011027927 W US 2011027927W WO 2011112828 A1 WO2011112828 A1 WO 2011112828A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- phenyl
- methyl
- dimethoxyphenyl
- bromo
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 148
- 239000000203 mixture Substances 0.000 title abstract description 114
- 239000003112 inhibitor Substances 0.000 title description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 176
- 241001465754 Metazoa Species 0.000 claims abstract description 40
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 18
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 12
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 9
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 9
- 206010015037 epilepsy Diseases 0.000 claims abstract description 7
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 5
- 208000024254 Delusional disease Diseases 0.000 claims abstract description 5
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 5
- 208000016285 Movement disease Diseases 0.000 claims abstract description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims abstract description 5
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 5
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 208000019906 panic disease Diseases 0.000 claims abstract description 5
- 208000002851 paranoid schizophrenia Diseases 0.000 claims abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 4
- 208000006373 Bell palsy Diseases 0.000 claims abstract description 4
- 208000002193 Pain Diseases 0.000 claims abstract description 4
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims abstract description 4
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims abstract description 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 4
- 208000016620 Tourette disease Diseases 0.000 claims abstract description 4
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims abstract description 4
- 201000007201 aphasia Diseases 0.000 claims abstract description 4
- 206010008129 cerebral palsy Diseases 0.000 claims abstract description 4
- 201000002545 drug psychosis Diseases 0.000 claims abstract description 4
- 206010014599 encephalitis Diseases 0.000 claims abstract description 4
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- 208000019899 phobic disease Diseases 0.000 claims abstract description 4
- 208000019116 sleep disease Diseases 0.000 claims abstract description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 81
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 78
- -1 4-bromo-3,5- dimethoxyphenyl Chemical group 0.000 claims description 53
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 6
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 208000035548 disruptive behavior disease Diseases 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- AVMAWOWPDZNGLB-UHFFFAOYSA-N 1-[5-(4-bromo-3,5-dimethoxyphenyl)furan-2-yl]-2-methoxy-2-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]ethanone Chemical compound C=1C=C(C=2SC(C)=NN=2)C=CC=1C(OC)C(=O)C(O1)=CC=C1C1=CC(OC)=C(Br)C(OC)=C1 AVMAWOWPDZNGLB-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 10
- 229940002612 prodrug Drugs 0.000 abstract description 9
- 239000000651 prodrug Substances 0.000 abstract description 9
- 239000012453 solvate Substances 0.000 abstract description 5
- 230000036506 anxiety Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 196
- 238000000746 purification Methods 0.000 description 155
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 134
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- 238000004587 chromatography analysis Methods 0.000 description 111
- 235000019439 ethyl acetate Nutrition 0.000 description 100
- 239000007787 solid Substances 0.000 description 97
- 239000000243 solution Substances 0.000 description 96
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 82
- 239000000047 product Substances 0.000 description 79
- 230000004044 response Effects 0.000 description 63
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 59
- 239000012267 brine Substances 0.000 description 56
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 56
- 239000003981 vehicle Substances 0.000 description 50
- 229920006395 saturated elastomer Polymers 0.000 description 47
- 238000003756 stirring Methods 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 46
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 45
- 238000003786 synthesis reaction Methods 0.000 description 44
- 229910052786 argon Inorganic materials 0.000 description 41
- 230000015572 biosynthetic process Effects 0.000 description 41
- 239000010410 layer Substances 0.000 description 40
- 239000003921 oil Substances 0.000 description 40
- 235000019198 oils Nutrition 0.000 description 40
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- BREGVWMWIKQGKG-UHFFFAOYSA-N 2-(4-bromo-3,5-dimethoxyphenyl)furan Chemical compound COC1=C(Br)C(OC)=CC(C=2OC=CC=2)=C1 BREGVWMWIKQGKG-UHFFFAOYSA-N 0.000 description 28
- 229910001868 water Inorganic materials 0.000 description 28
- 230000001143 conditioned effect Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 22
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 21
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 21
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 20
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 238000001816 cooling Methods 0.000 description 19
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 208000013403 hyperactivity Diseases 0.000 description 18
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- 238000003305 oral gavage Methods 0.000 description 16
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 14
- 239000006260 foam Substances 0.000 description 14
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 238000011740 C57BL/6 mouse Methods 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- YZVPNFQTHCNORA-UHFFFAOYSA-N 4-(4-bromo-3,5-dimethoxyphenyl)-1,3-oxazole Chemical compound COC1=C(Br)C(OC)=CC(C=2N=COC=2)=C1 YZVPNFQTHCNORA-UHFFFAOYSA-N 0.000 description 9
- 229960005017 olanzapine Drugs 0.000 description 9
- 238000007427 paired t-test Methods 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 8
- 239000000164 antipsychotic agent Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 230000001473 noxious effect Effects 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- 230000035939 shock Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229940005529 antipsychotics Drugs 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229950005228 bromoform Drugs 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000007928 intraperitoneal injection Substances 0.000 description 7
- 239000003368 psychostimulant agent Substances 0.000 description 7
- 238000012549 training Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- PUJSZNONTPWTHD-UHFFFAOYSA-N 2-(4-chloro-3,5-dimethoxyphenyl)furan Chemical compound COC1=C(Cl)C(OC)=CC(C=2OC=CC=2)=C1 PUJSZNONTPWTHD-UHFFFAOYSA-N 0.000 description 5
- UGBJRYUNSXFPOX-UHFFFAOYSA-N 4-bromo-3,5-dimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1Br UGBJRYUNSXFPOX-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102000016267 Leptin Human genes 0.000 description 5
- 108010092277 Leptin Proteins 0.000 description 5
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 5
- 235000019502 Orange oil Nutrition 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000010832 independent-sample T-test Methods 0.000 description 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 5
- 229940039781 leptin Drugs 0.000 description 5
- 230000006742 locomotor activity Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 239000010502 orange oil Substances 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- HHWKCCHNPJFHBV-UHFFFAOYSA-N 2-(4-bromo-3,5-dimethoxyphenyl)thiophene Chemical compound COC1=C(Br)C(OC)=CC(C=2SC=CC=2)=C1 HHWKCCHNPJFHBV-UHFFFAOYSA-N 0.000 description 4
- QJRWPPSUXPVLNN-UHFFFAOYSA-N 2-bromo-1-(4-bromo-3,5-dimethoxyphenyl)ethanone Chemical compound COC1=CC(C(=O)CBr)=CC(OC)=C1Br QJRWPPSUXPVLNN-UHFFFAOYSA-N 0.000 description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- GVDABYGXMSVFNC-UHFFFAOYSA-N 2-methoxy-2-(4-morpholin-4-ylphenyl)acetic acid Chemical compound C1=CC(C(C(O)=O)OC)=CC=C1N1CCOCC1 GVDABYGXMSVFNC-UHFFFAOYSA-N 0.000 description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 229910003827 NRaRb Inorganic materials 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000005840 aryl radicals Chemical class 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical group C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 4
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- GYGSNTBGHISKLR-UHFFFAOYSA-N (3-bromo-4,5-dimethoxyphenyl) trifluoromethanesulfonate Chemical compound COC1=CC(OS(=O)(=O)C(F)(F)F)=CC(Br)=C1OC GYGSNTBGHISKLR-UHFFFAOYSA-N 0.000 description 3
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 3
- AVVLKEDPCPDGFT-UHFFFAOYSA-N 2-(3,4,5-trimethoxyphenyl)furan Chemical compound COC1=C(OC)C(OC)=CC(C=2OC=CC=2)=C1 AVVLKEDPCPDGFT-UHFFFAOYSA-N 0.000 description 3
- KSXAXHPADJPYQP-UHFFFAOYSA-N 2-(4-fluoro-3,5-dimethoxyphenyl)furan Chemical compound COC1=C(F)C(OC)=CC(C=2OC=CC=2)=C1 KSXAXHPADJPYQP-UHFFFAOYSA-N 0.000 description 3
- BZKTUEJEODMMRN-UHFFFAOYSA-N 2-methoxy-2-(4-pyridin-3-ylphenyl)acetic acid Chemical compound C1=CC(C(C(O)=O)OC)=CC=C1C1=CC=CN=C1 BZKTUEJEODMMRN-UHFFFAOYSA-N 0.000 description 3
- CVXFLEVTFLQKQK-UHFFFAOYSA-N 2-methoxy-2-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]acetic acid Chemical compound C1=CC(C(C(O)=O)OC)=CC=C1C1=CSC(C)=N1 CVXFLEVTFLQKQK-UHFFFAOYSA-N 0.000 description 3
- DKNYCSZTOXNGBT-UHFFFAOYSA-N 2-methoxy-2-[4-(morpholin-4-ylmethyl)phenyl]acetic acid Chemical compound C1=CC(C(C(O)=O)OC)=CC=C1CN1CCOCC1 DKNYCSZTOXNGBT-UHFFFAOYSA-N 0.000 description 3
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 3
- KOUSUSBFSYVBFK-UHFFFAOYSA-N 3-bromo-4,5-dimethoxyphenol Chemical compound COC1=CC(O)=CC(Br)=C1OC KOUSUSBFSYVBFK-UHFFFAOYSA-N 0.000 description 3
- RNBPRCXUDBOYBU-UHFFFAOYSA-N 4-(4-bromo-3,5-dimethoxyphenyl)-1,3-thiazole Chemical compound COC1=C(Br)C(OC)=CC(C=2N=CSC=2)=C1 RNBPRCXUDBOYBU-UHFFFAOYSA-N 0.000 description 3
- GEMFEUIHLRJJCD-UHFFFAOYSA-N 4-(4-bromo-3,5-dimethoxyphenyl)-5-methyl-1,3-oxazole Chemical compound COC1=C(Br)C(OC)=CC(C2=C(OC=N2)C)=C1 GEMFEUIHLRJJCD-UHFFFAOYSA-N 0.000 description 3
- VKXCKVRDDDEQOG-UHFFFAOYSA-N 4-bromo-2,6-dimethoxyphenol Chemical compound COC1=CC(Br)=CC(OC)=C1O VKXCKVRDDDEQOG-UHFFFAOYSA-N 0.000 description 3
- FOAQOAXQMISINY-UHFFFAOYSA-N 4-morpholin-4-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CCOCC1 FOAQOAXQMISINY-UHFFFAOYSA-N 0.000 description 3
- LPCWYXJOFJJYQJ-UHFFFAOYSA-N 5-(4-bromo-3,5-dimethoxyphenyl)-1,3-oxazole Chemical compound COC1=C(Br)C(OC)=CC(C=2OC=NC=2)=C1 LPCWYXJOFJJYQJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000012074 GAF domains Human genes 0.000 description 3
- 108050002598 GAF domains Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- 229940127236 atypical antipsychotics Drugs 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical group C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- JVZJROVJKLMRMO-UHFFFAOYSA-N methyl 2-[4-(3-chloropropylsulfonylamino)phenyl]-2-methoxyacetate Chemical compound COC(=O)C(OC)C1=CC=C(NS(=O)(=O)CCCCl)C=C1 JVZJROVJKLMRMO-UHFFFAOYSA-N 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- MYCAOHQYISWJJT-UHFFFAOYSA-N (3,5-dimethoxy-4-methylphenyl) formate Chemical compound COC1=CC(OC=O)=CC(OC)=C1C MYCAOHQYISWJJT-UHFFFAOYSA-N 0.000 description 2
- PXMLGEZKVOKUQU-UHFFFAOYSA-N (3,5-dimethoxy-4-methylphenyl) trifluoromethanesulfonate Chemical compound COC1=CC(OS(=O)(=O)C(F)(F)F)=CC(OC)=C1C PXMLGEZKVOKUQU-UHFFFAOYSA-N 0.000 description 2
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- BEGNJBPPGFTSGV-UHFFFAOYSA-N 2-(1-ethoxyethoxy)-3-methoxy-3-(4-morpholin-4-ylphenyl)propanenitrile Chemical compound C1=CC(C(OC)C(C#N)OC(C)OCC)=CC=C1N1CCOCC1 BEGNJBPPGFTSGV-UHFFFAOYSA-N 0.000 description 2
- KWWVPFVUZGJCOC-UHFFFAOYSA-N 2-(3,5-dimethoxy-4-methylphenyl)furan Chemical compound COC1=C(C)C(OC)=CC(C=2OC=CC=2)=C1 KWWVPFVUZGJCOC-UHFFFAOYSA-N 0.000 description 2
- ADJXFJVZGUSTKS-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)furan Chemical compound COC1=CC(OC)=CC(C=2OC=CC=2)=C1 ADJXFJVZGUSTKS-UHFFFAOYSA-N 0.000 description 2
- IEIGQHYGJPGNGQ-UHFFFAOYSA-N 2-(3-bromo-4,5-dimethoxyphenyl)furan Chemical compound BrC1=C(OC)C(OC)=CC(C=2OC=CC=2)=C1 IEIGQHYGJPGNGQ-UHFFFAOYSA-N 0.000 description 2
- JOJXYOHSGUPGBF-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-3,5-dimethoxyphenyl]furan Chemical compound COC1=C(OC(F)F)C(OC)=CC(C=2OC=CC=2)=C1 JOJXYOHSGUPGBF-UHFFFAOYSA-N 0.000 description 2
- VAPRMCXMIDXLTR-UHFFFAOYSA-N 2-[4-[(dimethylamino)methyl]phenyl]-2-methoxyacetic acid Chemical compound COC(C(O)=O)C1=CC=C(CN(C)C)C=C1 VAPRMCXMIDXLTR-UHFFFAOYSA-N 0.000 description 2
- TXPVWKCVCWXUIS-UHFFFAOYSA-N 2-bromo-1-(4-bromo-3,5-dimethoxyphenyl)propan-1-one Chemical compound COC1=CC(C(=O)C(C)Br)=CC(OC)=C1Br TXPVWKCVCWXUIS-UHFFFAOYSA-N 0.000 description 2
- GBBWHOUPJUHSRD-UHFFFAOYSA-N 2-bromo-5-iodo-1,3-dimethoxybenzene Chemical compound COC1=CC(I)=CC(OC)=C1Br GBBWHOUPJUHSRD-UHFFFAOYSA-N 0.000 description 2
- ALVGVCRCSDONPF-UHFFFAOYSA-N 2-ethoxy-2-(4-morpholin-4-ylphenyl)acetic acid Chemical compound C1=CC(C(C(O)=O)OCC)=CC=C1N1CCOCC1 ALVGVCRCSDONPF-UHFFFAOYSA-N 0.000 description 2
- JLOYOMKYEYPMGL-UHFFFAOYSA-N 2-methoxy-2-(4-nitrophenyl)acetic acid Chemical compound COC(C(O)=O)C1=CC=C([N+]([O-])=O)C=C1 JLOYOMKYEYPMGL-UHFFFAOYSA-N 0.000 description 2
- RQPYOTWQSFNVNJ-UHFFFAOYSA-N 2-methoxy-2-(4-propan-2-yloxyphenyl)acetic acid Chemical compound COC(C(O)=O)C1=CC=C(OC(C)C)C=C1 RQPYOTWQSFNVNJ-UHFFFAOYSA-N 0.000 description 2
- XZPIRGQOKDQHGG-UHFFFAOYSA-N 2-methoxy-2-(4-pyrazin-2-ylphenyl)acetic acid Chemical compound C1=CC(C(C(O)=O)OC)=CC=C1C1=CN=CC=N1 XZPIRGQOKDQHGG-UHFFFAOYSA-N 0.000 description 2
- PNMXUYQEGGJNSG-UHFFFAOYSA-N 2-methoxy-2-(6-methoxypyridin-3-yl)acetic acid Chemical compound COC(C(O)=O)C1=CC=C(OC)N=C1 PNMXUYQEGGJNSG-UHFFFAOYSA-N 0.000 description 2
- JILPHPANERZNKO-UHFFFAOYSA-N 2-methoxy-2-(6-morpholin-4-ylpyridin-3-yl)acetic acid Chemical compound N1=CC(C(C(O)=O)OC)=CC=C1N1CCOCC1 JILPHPANERZNKO-UHFFFAOYSA-N 0.000 description 2
- MPPHZUYEHUVVSY-UHFFFAOYSA-N 2-methoxy-2-(6-piperidin-1-ylpyridin-3-yl)acetic acid Chemical compound N1=CC(C(C(O)=O)OC)=CC=C1N1CCCCC1 MPPHZUYEHUVVSY-UHFFFAOYSA-N 0.000 description 2
- ZEIJTVMNRYBFSU-UHFFFAOYSA-N 2-methoxy-2-[4-(5-methylfuran-2-yl)phenyl]acetic acid Chemical compound C1=CC(C(C(O)=O)OC)=CC=C1C1=CC=C(C)O1 ZEIJTVMNRYBFSU-UHFFFAOYSA-N 0.000 description 2
- MBNLKBYLPMCNJQ-UHFFFAOYSA-N 2-methoxy-2-quinolin-5-ylacetic acid Chemical compound C1=CC=C2C(C(C(O)=O)OC)=CC=CC2=N1 MBNLKBYLPMCNJQ-UHFFFAOYSA-N 0.000 description 2
- UXGHDWLJFHAOMB-UHFFFAOYSA-N 3,5-dimethoxy-4-methylphenol Chemical compound COC1=CC(O)=CC(OC)=C1C UXGHDWLJFHAOMB-UHFFFAOYSA-N 0.000 description 2
- IFMKXAWHVGQBMB-UHFFFAOYSA-N 3-chloro-4,5-dimethoxyphenol Chemical compound COC1=CC(O)=CC(Cl)=C1OC IFMKXAWHVGQBMB-UHFFFAOYSA-N 0.000 description 2
- UFPXFKLTIBFDTP-UHFFFAOYSA-N 4-(furan-2-yl)-2,6-dimethoxyphenol Chemical compound COC1=C(O)C(OC)=CC(C=2OC=CC=2)=C1 UFPXFKLTIBFDTP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- XFLJIJCRXQRBSO-UHFFFAOYSA-N 5-(furan-2-yl)-2,3-dimethoxybenzonitrile Chemical compound N#CC1=C(OC)C(OC)=CC(C=2OC=CC=2)=C1 XFLJIJCRXQRBSO-UHFFFAOYSA-N 0.000 description 2
- VGBXIVCHRYEAJG-UHFFFAOYSA-N CN(C(C(c(cc1)ccc1N1CCOCC1)OC)=O)OC Chemical compound CN(C(C(c(cc1)ccc1N1CCOCC1)OC)=O)OC VGBXIVCHRYEAJG-UHFFFAOYSA-N 0.000 description 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 2
- 101100351286 Dictyostelium discoideum pdeE gene Proteins 0.000 description 2
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 101150098694 PDE5A gene Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 2
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 2
- 206010042008 Stereotypy Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- HLLJGBXQABOJTR-UHFFFAOYSA-N [4-(furan-2-yl)-2,6-dimethoxyphenyl] benzoate Chemical compound COC1=CC(C=2OC=CC=2)=CC(OC)=C1OC(=O)C1=CC=CC=C1 HLLJGBXQABOJTR-UHFFFAOYSA-N 0.000 description 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical group C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical group C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical group C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000000848 glutamatergic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- RMQXPBMZIWZIRC-UHFFFAOYSA-N methyl 2-(4-aminophenyl)-2-methoxyacetate Chemical compound COC(=O)C(OC)C1=CC=C(N)C=C1 RMQXPBMZIWZIRC-UHFFFAOYSA-N 0.000 description 2
- XNNGAXLWDZQVGY-UHFFFAOYSA-N methyl 2-methoxy-2-(4-nitrophenyl)acetate Chemical compound COC(=O)C(OC)C1=CC=C([N+]([O-])=O)C=C1 XNNGAXLWDZQVGY-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 101150037969 pde-6 gene Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- CKOOABJZYWLHMN-UHFFFAOYSA-N phenyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC1=CC=CC=C1.C=1C=CC=CC=1C(=O)OC1=CC=CC=C1 CKOOABJZYWLHMN-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000002385 psychotomimetic effect Effects 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical group C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- BNEVFKZLYCGDFG-UHFFFAOYSA-N quinoline-5-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=N1 BNEVFKZLYCGDFG-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- SRRKNRDXURUMPP-UHFFFAOYSA-N sodium disulfide Chemical compound [Na+].[Na+].[S-][S-] SRRKNRDXURUMPP-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FCMLWBBLOASUSO-UHFFFAOYSA-N tert-butyl 3-oxopiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(=O)C1 FCMLWBBLOASUSO-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- HJNVVNJXIUTKJH-UHFFFAOYSA-N (3-chloro-4,5-dimethoxyphenyl) trifluoromethanesulfonate Chemical compound COC1=CC(OS(=O)(=O)C(F)(F)F)=CC(Cl)=C1OC HJNVVNJXIUTKJH-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 1,2-dimethoxyethane;hydrate Chemical compound O.COCCOC ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 0.000 description 1
- ZXOFAHRGRROAQR-UHFFFAOYSA-N 1-(isocyanomethylsulfonyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1S(=O)(=O)C[N+]#[C-] ZXOFAHRGRROAQR-UHFFFAOYSA-N 0.000 description 1
- VLAONBBWRMWLEB-UHFFFAOYSA-N 1-[4-(4-bromo-3,5-dimethoxyphenyl)-1,3-oxazol-2-yl]-2-methoxy-2-(4-morpholin-4-ylphenyl)ethanone Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(OC)C(=O)C(OC=1)=NC=1C1=CC(OC)=C(Br)C(OC)=C1 VLAONBBWRMWLEB-UHFFFAOYSA-N 0.000 description 1
- KGXXSGCCKWBIGI-UHFFFAOYSA-N 1-[4-(4-bromo-3,5-dimethoxyphenyl)-1,3-thiazol-2-yl]-2-methoxy-2-(4-morpholin-4-ylphenyl)ethanone Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(OC)C(=O)C(SC=1)=NC=1C1=CC(OC)=C(Br)C(OC)=C1 KGXXSGCCKWBIGI-UHFFFAOYSA-N 0.000 description 1
- CYDNAQNJKMXXFL-UHFFFAOYSA-N 1-[5-(3,5-dimethoxyphenyl)furan-2-yl]-2-methoxy-2-(4-morpholin-4-ylphenyl)ethanone Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(OC)C(=O)C(O1)=CC=C1C1=CC(OC)=CC(OC)=C1 CYDNAQNJKMXXFL-UHFFFAOYSA-N 0.000 description 1
- CISMPXIGSBNBME-UHFFFAOYSA-N 1-[5-(4-bromo-3,5-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-methoxy-2-(4-morpholin-4-ylphenyl)ethanone Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(OC)C(=O)C(N=1)=NOC=1C1=CC(OC)=C(Br)C(OC)=C1 CISMPXIGSBNBME-UHFFFAOYSA-N 0.000 description 1
- LBYXMNLUXVVTNH-UHFFFAOYSA-N 1-[5-(4-bromo-3,5-dimethoxyphenyl)furan-2-yl]-2-methoxy-2-(4-morpholin-4-ylphenyl)ethanone Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(OC)C(=O)C(O1)=CC=C1C1=CC(OC)=C(Br)C(OC)=C1 LBYXMNLUXVVTNH-UHFFFAOYSA-N 0.000 description 1
- XLBUVWKTLGKYGB-UHFFFAOYSA-N 1-[5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl]-2-ethoxy-2-(4-morpholin-4-ylphenyl)ethanone Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(OCC)C(=O)C(O1)=CC=C1C1=CC(OC)=C(Cl)C(OC)=C1 XLBUVWKTLGKYGB-UHFFFAOYSA-N 0.000 description 1
- WAWDNLMYAKSZJR-UHFFFAOYSA-N 1-[5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl]-2-methoxy-2-(4-morpholin-4-ylphenyl)ethanone Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(OC)C(=O)C(O1)=CC=C1C1=CC(OC)=C(Cl)C(OC)=C1 WAWDNLMYAKSZJR-UHFFFAOYSA-N 0.000 description 1
- GOMFKINUJCNTRG-UHFFFAOYSA-N 1-[5-(4-ethoxy-3,5-dimethoxyphenyl)furan-2-yl]-2-methoxy-2-(4-morpholin-4-ylphenyl)ethanone Chemical compound C1=C(OC)C(OCC)=C(OC)C=C1C1=CC=C(C(=O)C(OC)C=2C=CC(=CC=2)N2CCOCC2)O1 GOMFKINUJCNTRG-UHFFFAOYSA-N 0.000 description 1
- QRADKVYIJIAENZ-UHFFFAOYSA-N 1-[[bromo(difluoro)methyl]-ethoxyphosphoryl]oxyethane Chemical compound CCOP(=O)(C(F)(F)Br)OCC QRADKVYIJIAENZ-UHFFFAOYSA-N 0.000 description 1
- OBFCMKPFILBCSQ-UHFFFAOYSA-N 1-[chloro-bis(4-methoxyphenyl)methyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 OBFCMKPFILBCSQ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- DVZCWZIPYBRTIF-UHFFFAOYSA-N 2,3-dimethoxy-5-[5-[2-methoxy-2-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]acetyl]furan-2-yl]benzonitrile Chemical compound C=1C=C(C=2OC(C)=NN=2)C=CC=1C(OC)C(=O)C(O1)=CC=C1C1=CC(OC)=C(OC)C(C#N)=C1 DVZCWZIPYBRTIF-UHFFFAOYSA-N 0.000 description 1
- 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- UTAZBQMBWVPNET-UHFFFAOYSA-N 2-(3-chloro-4,5-dimethoxyphenyl)furan Chemical compound ClC1=C(OC)C(OC)=CC(C=2OC=CC=2)=C1 UTAZBQMBWVPNET-UHFFFAOYSA-N 0.000 description 1
- IURBWGPNQQQIHQ-UHFFFAOYSA-N 2-(4-ethoxy-3,5-dimethoxyphenyl)furan Chemical compound C1=C(OC)C(OCC)=C(OC)C=C1C1=CC=CO1 IURBWGPNQQQIHQ-UHFFFAOYSA-N 0.000 description 1
- XSSNXGQLLDQUCF-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-methoxyacetic acid Chemical compound COC(C(O)=O)C1=CC=C(F)C=C1 XSSNXGQLLDQUCF-UHFFFAOYSA-N 0.000 description 1
- VPTHRMOQQFCINW-UHFFFAOYSA-N 2-(4-morpholin-4-ylphenyl)propanamide Chemical compound C1=CC(C(C(N)=O)C)=CC=C1N1CCOCC1 VPTHRMOQQFCINW-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- DVDFQFRVDODOLY-UHFFFAOYSA-N 2-hydroxy-3-methoxy-3-(4-morpholin-4-ylphenyl)propanenitrile Chemical compound C1=CC(C(C(O)C#N)OC)=CC=C1N1CCOCC1 DVDFQFRVDODOLY-UHFFFAOYSA-N 0.000 description 1
- BNUVNGSMUMAXBW-UHFFFAOYSA-N 2-methoxy-2-(4-morpholin-4-ylphenyl)acetaldehyde Chemical compound C1=CC(C(C=O)OC)=CC=C1N1CCOCC1 BNUVNGSMUMAXBW-UHFFFAOYSA-N 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- MVYZXQMGSYROEH-UHFFFAOYSA-N 3,5-dimethoxy-4-methylbenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1C MVYZXQMGSYROEH-UHFFFAOYSA-N 0.000 description 1
- ICVODPFGWCUVJC-UHFFFAOYSA-N 3-bromo-4,5-dimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(Br)=C1OC ICVODPFGWCUVJC-UHFFFAOYSA-N 0.000 description 1
- AMZCHEDPEAQEMC-UHFFFAOYSA-N 3-chloro-4,5-dimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(Cl)=C1OC AMZCHEDPEAQEMC-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- GPKDGVXBXQTHRY-UHFFFAOYSA-N 3-chloropropane-1-sulfonyl chloride Chemical compound ClCCCS(Cl)(=O)=O GPKDGVXBXQTHRY-UHFFFAOYSA-N 0.000 description 1
- 125000006027 3-methyl-1-butenyl group Chemical group 0.000 description 1
- DBYDKNMKDVNUIJ-UHFFFAOYSA-N 4-(4-bromo-3,5-dimethoxyphenyl)-5-(trifluoromethyl)-1,3-oxazole Chemical compound COC1=C(Br)C(OC)=CC(C2=C(OC=N2)C(F)(F)F)=C1 DBYDKNMKDVNUIJ-UHFFFAOYSA-N 0.000 description 1
- XVPPZRZUEUFYSM-UHFFFAOYSA-N 4-(5-methylfuran-2-yl)benzaldehyde Chemical compound O1C(C)=CC=C1C1=CC=C(C=O)C=C1 XVPPZRZUEUFYSM-UHFFFAOYSA-N 0.000 description 1
- KMAHWHPUXGNVBN-UHFFFAOYSA-N 4-(morpholin-4-ylmethyl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1CN1CCOCC1 KMAHWHPUXGNVBN-UHFFFAOYSA-N 0.000 description 1
- HQDFSQZWAINMKA-UHFFFAOYSA-N 4-[(dimethylamino)methyl]benzaldehyde Chemical compound CN(C)CC1=CC=C(C=O)C=C1 HQDFSQZWAINMKA-UHFFFAOYSA-N 0.000 description 1
- MLASCKILMYIEBF-UHFFFAOYSA-N 4-[[tert-butyl(dimethyl)silyl]oxymethyl]benzohydrazide Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=C(C(=O)NN)C=C1 MLASCKILMYIEBF-UHFFFAOYSA-N 0.000 description 1
- WVGCPEDBFHEHEZ-UHFFFAOYSA-N 4-bromo-1h-pyrazole Chemical compound BrC=1C=NNC=1 WVGCPEDBFHEHEZ-UHFFFAOYSA-N 0.000 description 1
- MJINXEUETHLORE-UHFFFAOYSA-N 4-bromo-3,5-dimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1Br MJINXEUETHLORE-UHFFFAOYSA-N 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- ILJVPSVCFVQUAD-UHFFFAOYSA-N 4-piperidin-1-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CCCCC1 ILJVPSVCFVQUAD-UHFFFAOYSA-N 0.000 description 1
- WDANSDASCKBVKH-UHFFFAOYSA-N 4-propan-2-yloxybenzaldehyde Chemical compound CC(C)OC1=CC=C(C=O)C=C1 WDANSDASCKBVKH-UHFFFAOYSA-N 0.000 description 1
- QEJFDPPZUXABRM-UHFFFAOYSA-N 4-pyrazin-2-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CN=CC=N1 QEJFDPPZUXABRM-UHFFFAOYSA-N 0.000 description 1
- NXZUVHZZIZHEOP-UHFFFAOYSA-N 4-pyridin-3-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CC=CN=C1 NXZUVHZZIZHEOP-UHFFFAOYSA-N 0.000 description 1
- DATXHLPRESKQJK-UHFFFAOYSA-N 4-pyrrolidin-1-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CCCC1 DATXHLPRESKQJK-UHFFFAOYSA-N 0.000 description 1
- XOSGJVLWCGRCCA-UHFFFAOYSA-N 5-(4-bromo-3,5-dimethoxyphenyl)-4-(4-methylphenyl)sulfonyl-4,5-dihydro-1,3-oxazole Chemical compound COC1=C(Br)C(OC)=CC(C2C(N=CO2)S(=O)(=O)C=2C=CC(C)=CC=2)=C1 XOSGJVLWCGRCCA-UHFFFAOYSA-N 0.000 description 1
- NSLPEHVFBDYXDV-UHFFFAOYSA-N 5-bromo-2,3-dimethoxybenzonitrile Chemical compound COC1=CC(Br)=CC(C#N)=C1OC NSLPEHVFBDYXDV-UHFFFAOYSA-N 0.000 description 1
- CTAIEPPAOULMFY-UHFFFAOYSA-N 6-methoxypyridine-3-carbaldehyde Chemical compound COC1=CC=C(C=O)C=N1 CTAIEPPAOULMFY-UHFFFAOYSA-N 0.000 description 1
- VZEANTSDLFVWCK-UHFFFAOYSA-N 6-morpholin-4-ylpyridine-3-carbaldehyde Chemical compound N1=CC(C=O)=CC=C1N1CCOCC1 VZEANTSDLFVWCK-UHFFFAOYSA-N 0.000 description 1
- RKIMIISNVCLRLA-UHFFFAOYSA-N 6-piperidin-1-ylpyridine-3-carbaldehyde Chemical compound N1=CC(C=O)=CC=C1N1CCCCC1 RKIMIISNVCLRLA-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000192542 Anabaena Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 0 C*c(cc(cc1OC)C(Cl)=O)c1Br Chemical compound C*c(cc(cc1OC)C(Cl)=O)c1Br 0.000 description 1
- IZASECTUZQTFOB-JCMHNJIXSA-N CC(C(C(c(cc1)ccc1N1CCOCC1)OC)=O)O/C(/c(cc1OC)cc(OC)c1Br)=C\N Chemical compound CC(C(C(c(cc1)ccc1N1CCOCC1)OC)=O)O/C(/c(cc1OC)cc(OC)c1Br)=C\N IZASECTUZQTFOB-JCMHNJIXSA-N 0.000 description 1
- ABLOQZJAIJJQMB-UHFFFAOYSA-N CC(C)Oc1ccc(C(C(c2nc(-c(cc3OC)cc(OC)c3Br)c[o]2)=O)OC)cc1 Chemical compound CC(C)Oc1ccc(C(C(c2nc(-c(cc3OC)cc(OC)c3Br)c[o]2)=O)OC)cc1 ABLOQZJAIJJQMB-UHFFFAOYSA-N 0.000 description 1
- VDCBJUKCWXUXSO-UHFFFAOYSA-N CC(C1)C(C(C(N(C)OC)O)OC)=CC=C1N(CCC1)S1(=O)=O Chemical compound CC(C1)C(C(C(N(C)OC)O)OC)=CC=C1N(CCC1)S1(=O)=O VDCBJUKCWXUXSO-UHFFFAOYSA-N 0.000 description 1
- QOQQUURINRHFKP-UHFFFAOYSA-N CC1=NCC(CO)S1 Chemical compound CC1=NCC(CO)S1 QOQQUURINRHFKP-UHFFFAOYSA-N 0.000 description 1
- OPJNELZTZYMLLU-UHFFFAOYSA-N CCOC(C)OC(C(c(cc1)ccc1N1CCOCC1)OC)c1n[o]c(-c(cc2OC)cc(OC)c2Br)n1 Chemical compound CCOC(C)OC(C(c(cc1)ccc1N1CCOCC1)OC)c1n[o]c(-c(cc2OC)cc(OC)c2Br)n1 OPJNELZTZYMLLU-UHFFFAOYSA-N 0.000 description 1
- SQVYYAYVRVAMGI-UHFFFAOYSA-N CN(C(C(c(cc1)ccc1-[n]1ncnc1)OC)=O)OC Chemical compound CN(C(C(c(cc1)ccc1-[n]1ncnc1)OC)=O)OC SQVYYAYVRVAMGI-UHFFFAOYSA-N 0.000 description 1
- AYGXANHJHMKLHV-UHFFFAOYSA-N CN(C(C(c(cc1)ccc1-c1cnccc1)OC)=O)OC Chemical compound CN(C(C(c(cc1)ccc1-c1cnccc1)OC)=O)OC AYGXANHJHMKLHV-UHFFFAOYSA-N 0.000 description 1
- DGPKWSCRXJDASE-UHFFFAOYSA-N CN(C(C(c(cc1)ccc1-c1nccnc1)OC)=O)OC Chemical compound CN(C(C(c(cc1)ccc1-c1nccnc1)OC)=O)OC DGPKWSCRXJDASE-UHFFFAOYSA-N 0.000 description 1
- YXYUVBSJGNHYBQ-UHFFFAOYSA-N CN(C(C(c(cc1)ccc1N1CCOCC1)OCC1CC1)=O)OC Chemical compound CN(C(C(c(cc1)ccc1N1CCOCC1)OCC1CC1)=O)OC YXYUVBSJGNHYBQ-UHFFFAOYSA-N 0.000 description 1
- PWXIBEFNVUOZLP-UHFFFAOYSA-N CN(C(C(c1ccc(CN2CCOCC2)cc1)OC)=O)OC Chemical compound CN(C(C(c1ccc(CN2CCOCC2)cc1)OC)=O)OC PWXIBEFNVUOZLP-UHFFFAOYSA-N 0.000 description 1
- NDMXNLNKNRTNAB-UHFFFAOYSA-N CN(C(C(c1cccc2ncccc12)OC)=O)OC Chemical compound CN(C(C(c1cccc2ncccc12)OC)=O)OC NDMXNLNKNRTNAB-UHFFFAOYSA-N 0.000 description 1
- BYBIIHCJDPNFCS-UHFFFAOYSA-N COC(C(O)=O)c(cc1)ccc1-[n]1nncc1 Chemical compound COC(C(O)=O)c(cc1)ccc1-[n]1nncc1 BYBIIHCJDPNFCS-UHFFFAOYSA-N 0.000 description 1
- UNQFGQMSTSZQSN-UHFFFAOYSA-N COC(C(OC)=O)c(cc1)ccc1N(CCC1)S1(=O)=O Chemical compound COC(C(OC)=O)c(cc1)ccc1N(CCC1)S1(=O)=O UNQFGQMSTSZQSN-UHFFFAOYSA-N 0.000 description 1
- AHWCEBOYNYEUHZ-UHFFFAOYSA-N COC(C(c1ccc(-c(cc2OC)cc(OC)c2Br)[o]1)=O)c(cc1)ccc1-[n]1ncnc1 Chemical compound COC(C(c1ccc(-c(cc2OC)cc(OC)c2Br)[o]1)=O)c(cc1)ccc1-[n]1ncnc1 AHWCEBOYNYEUHZ-UHFFFAOYSA-N 0.000 description 1
- WWRXGGMPISSEGO-UHFFFAOYSA-N COC(C(c1ccc(-c(cc2OC)cc(OC)c2Br)[o]1)=O)c(cc1)ccc1N(CCC1)S1(=O)=O Chemical compound COC(C(c1ccc(-c(cc2OC)cc(OC)c2Br)[o]1)=O)c(cc1)ccc1N(CCC1)S1(=O)=O WWRXGGMPISSEGO-UHFFFAOYSA-N 0.000 description 1
- OECPZICMIXRJOG-UHFFFAOYSA-N COC(C(c1ccc(-c(cc2OC)cc(OC)c2Br)[o]1)=O)c1c(cccn2)c2ccc1 Chemical compound COC(C(c1ccc(-c(cc2OC)cc(OC)c2Br)[o]1)=O)c1c(cccn2)c2ccc1 OECPZICMIXRJOG-UHFFFAOYSA-N 0.000 description 1
- YZOPBMNWBUIUIC-UHFFFAOYSA-N COc1cc(-c2ccc(C(C(c(cc3)ccc3N3CCOCC3)OCC3CC3)=O)[o]2)cc(OC)c1Br Chemical compound COc1cc(-c2ccc(C(C(c(cc3)ccc3N3CCOCC3)OCC3CC3)=O)[o]2)cc(OC)c1Br YZOPBMNWBUIUIC-UHFFFAOYSA-N 0.000 description 1
- ZKOFKUBYGPXYGD-UHFFFAOYSA-N COc1cc(Br)cc(OC)c1OC(F)F Chemical compound COc1cc(Br)cc(OC)c1OC(F)F ZKOFKUBYGPXYGD-UHFFFAOYSA-N 0.000 description 1
- 101100243082 Caenorhabditis elegans pde-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- JYAZRPPZZPHLMO-UHFFFAOYSA-N Cc1c(-c(cc2OC)cc(OC)c2Br)nc(C(C(c(cc2)ccc2N2CCOCC2)OC)=O)[o]1 Chemical compound Cc1c(-c(cc2OC)cc(OC)c2Br)nc(C(C(c(cc2)ccc2N2CCOCC2)OC)=O)[o]1 JYAZRPPZZPHLMO-UHFFFAOYSA-N 0.000 description 1
- ISIWQSSFMZNPBC-UHFFFAOYSA-N Cc1nc(-c2ccc(C(C(c3ccc(-c(cc4OC)cc(OC)c4Br)[o]3)=O)OC)cc2)c[s]1 Chemical compound Cc1nc(-c2ccc(C(C(c3ccc(-c(cc4OC)cc(OC)c4Br)[o]3)=O)OC)cc2)c[s]1 ISIWQSSFMZNPBC-UHFFFAOYSA-N 0.000 description 1
- KZEOQFIBKXJGEX-UHFFFAOYSA-N Cc1nc(-c2ccc(C=O)cc2)c[s]1 Chemical compound Cc1nc(-c2ccc(C=O)cc2)c[s]1 KZEOQFIBKXJGEX-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000271537 Crotalus atrox Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 101100407340 Drosophila melanogaster Pde8 gene Proteins 0.000 description 1
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100407337 Mus musculus Pde8a gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- CUKGVKDSSJVBFD-UHFFFAOYSA-N O=Cc(cc1)ccc1-[n]1nncc1 Chemical compound O=Cc(cc1)ccc1-[n]1nncc1 CUKGVKDSSJVBFD-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000028810 Shared psychotic disease Diseases 0.000 description 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Chemical group C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Chemical group C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical group C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- SGEMMELRMUVIHJ-UHFFFAOYSA-N ethyl cyclopropanecarboximidate;hydrochloride Chemical compound Cl.CCOC(=N)C1CC1 SGEMMELRMUVIHJ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- ATZIPACKTBIFAX-UHFFFAOYSA-N ethyl propanimidate;hydrochloride Chemical compound Cl.CCOC(=N)CC ATZIPACKTBIFAX-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 101150060381 fhlA gene Proteins 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical group C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- PUYCICVJCRLABY-UHFFFAOYSA-N heptane;oxolane Chemical compound C1CCOC1.CCCCCCC PUYCICVJCRLABY-UHFFFAOYSA-N 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical class CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005468 isobutylenyl group Chemical group 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- JHHMSRLTZAUMOJ-UHFFFAOYSA-N methanamine;oxolane Chemical compound NC.C1CCOC1 JHHMSRLTZAUMOJ-UHFFFAOYSA-N 0.000 description 1
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- JTUQBOLVFVSYSB-UHFFFAOYSA-N n,2-dimethoxy-n-methyl-2-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]acetamide Chemical compound C1=CC(C(C(=O)N(C)OC)OC)=CC=C1C1=NN=C(C)O1 JTUQBOLVFVSYSB-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Chemical group C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical group C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical group C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- CASUWPDYGGAUQV-UHFFFAOYSA-M potassium;methanol;hydroxide Chemical compound [OH-].[K+].OC CASUWPDYGGAUQV-UHFFFAOYSA-M 0.000 description 1
- 230000006977 prepulse inhibition Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- VQGISNOMGHCEPX-UHFFFAOYSA-N propanenitrile Chemical compound C[CH]C#N VQGISNOMGHCEPX-UHFFFAOYSA-N 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000005470 propylenyl group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940127250 psychostimulant medication Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- CRUILBNAQILVHZ-UHFFFAOYSA-N pyrogallol trimethyl ether Natural products COC1=CC=CC(OC)=C1OC CRUILBNAQILVHZ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- RYGIHSLRMNXWCN-UHFFFAOYSA-N quinoline-3-carbaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CN=C21 RYGIHSLRMNXWCN-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical group C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004006 stereotypic behavior Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- KSKISSONZRPPSZ-UHFFFAOYSA-N tert-butyl-[[4-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)phenyl]methoxy]-dimethylsilane Chemical compound C1=CC(CO[Si](C)(C)C(C)(C)C)=CC=C1C1=NN=C(C2CC2)O1 KSKISSONZRPPSZ-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229940030010 trimethoxybenzene Drugs 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229940039925 zyprexa Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates generally to compounds having activity as PDE10 inhibitors, and to compositions containing the same, as well as to methods of treating various disorders by administration of such compounds to a warm-blooded animal in need thereof.
- Cyclic nucleotide phosphodiesterases are represented by a large superfamily of enzymes. PDEs are known to possess a modular architecture, with a conserved catalytic domain proximal to the carboxyl terminus, and regulatory domains or motifs often near the amino terminus. The PDE superfamily currently includes more than twenty different genes subgrouped into eleven PDE families (Lugnier, C, "Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.” Pharmacol Ther. 2006 Mar; 109(3):366-98).
- PDE10 A recently described PDE, PDE10, was reported simultaneously by three independent groups (Fujishige et al, "Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDEIOA),” J Biol Chem 1999, 274:18438-18445; Loughney et al., "Isolation and characterization of PDEIOA, a novel human 3', 5'-cyclic nucleotide phosphodiesterase," Gene 1999, 234:109-117; Soderling et al, "Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDEIOA,” Proc Natl Acad Set USA 1999, 96:7071-7076).
- PDE10 has the capacity to hydrolyze both cAMP and cGMP; however, the K m for cAMP is approximately 0.05 ⁇ , whereas the K M for cGMP is 3 ⁇ . In addition, the F max for cAMP hydrolysis is fivefold lower than for cGMP. Because of these kinetics, cGMP hydrolysis by PDE10 is potently inhibited by cAMP in vitro, suggesting that PDE10 may function as a cAMP-inhibited cGMP phosphodiesterase in vivo. Unlike PDE8 or PDE9, PDE10 is inhibited by IBMX with an IC 5 o (50% inhibitory concentration) of 2.6 ⁇ . (See Soderling and Beavo, "Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions," Current Opinion in Cell Biology, 2000, 12:174-179.)
- PDE10 contains two amino-terminal domains that are similar to the cGMP-binding domains of PDE2, PDE5 and PDE6, which are domains conserved across a wide variety of proteins. Because of the wide conservation of this domain, it is now referred to as the GAF domain (for the GAF proteins: cGMP binding phosphodiesterases; the cynobacterial Anabaena adenylyl cyclase; and the Escherichia coli transcriptional regulator fhlA). Although in PDE2, PDE5 and PDE6 the GAF domains bind cGMP, this is probably not the primary function of this domain in all cases ⁇ e.g., E. coli are not thought to synthesize cGMP).
- Inhibitors of the PDE family of enzymes have widely been sought for a broad indication of therapeutic uses.
- Reported therapeutic uses of PDE inhibitors include allergies, obtrusive lung disease, hypertension, renal carcinoma, angina, congestive heart failure, depression and erectile dysfunction (WO 01/41807 A2).
- Other inhibitors of PDE have been disclosed for treatment of ischemic heart conditions (U.S. Pat. No. 5,693,652).
- More specifically, inhibitors of PDE10 have been disclosed for treatment of certain neurological and psychiatric disorders including, Parkinson's disease, Huntington's disease, schizophrenia, delusional disorders, drag-induced psychosis and panic and obsessive-compulsive disorders (U.S. Patent Application No. 2003/0032579).
- PDE10 has been shown to be present at high levels in neurons in areas of the brain that are closely associated with many neurological and psychiatric disorders. By inhibiting PDE10 activity, levels of cAMP and cGMP are increased within neurons, and the ability of these neurons to function properly is thereby improved. Thus, inhibition of PDE10 is believed to be useful in the treatment of a wide variety of conditions or disorders that would benefit from increasing levels of cAMP and cGMP within neurons, including those neurological, psychotic, anxiety and/or movement disorders mentioned above.
- this invention is generally directed to compounds that have activity as PDE10 inhibitors, as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.
- the compounds have the following general structure
- the compounds of this invention have utility over a wide range of therapeutic applications, and may be used to treat a wide variety of conditions or disorders that would benefit from increasing levels of cAMP and cGMP, especially within neurons, including (but not limited to) neurological disorders, such as psychotic disorders, anxiety disorders, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, bipolar disorders, post-traumatic stress disorders, drug-induced psychosis, panic disorders, obsessive-compulsive disorders, attention-deficit disorders, disruptive behavior disorders, autism, depression, dementia, cognitive disorders, epilepsy, insomnias and multiple sclerosis.
- neurological disorders such as psychotic disorders, anxiety disorders, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias
- the methods of this invention include administering an effective amount of a compound of the foregoing structures, typically in the form of a pharmaceutical composition, to a mammal in need thereof, including a human.
- a pharmaceutical composition containing one or more compounds of the foregoing structures in combination with a pharmaceutically acceptable carrier or diluent.
- FIGURE 1 illustrates that Compound 1-1 of the present invention
- Example 1 administered by intraperitoneal injection significantly reduces hyperactivity of mice in a psychostimulant (PCP)-induced model of psychosis as compared to vehicle control.
- PCP psychostimulant
- FIGURE 2 illustrates that Compound 1-1 of the present invention
- Example 1 administered by oral gavage significantly reduces hyperactivity of mice in a psychostimulant (PCP)-induced model of psychosis as compared to vehicle control.
- PCP psychostimulant
- FIGURE 3 illustrates that Compound 2-1 of the present invention
- Example 2 administered by intraperitoneal injection significantly reduces hyperactivity of mice in a psychostimulant (PCP)-induced model of psychosis as compared to vehicle control.
- PCP psychostimulant
- FIGURE 4 illustrates that Compound 2-1 of the present invention (Example 2) administered by oral gavage significantly reduces hyperactivity of mice in a psychostimulant (PCP)-induced model of psychosis as compared to vehicle control.
- FIGURE 5 illustrates that Compound 2-1 of the present invention (Example 2) significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control.
- CAR conditioned avoidance response
- FIGURE 6 illustrates that Compound 11-1 of the present invention (Example 11) administered by intraperitoneal injection significantly reduces hyperactivity of mice in a psychostimulant (PCP)-induced model of psychosis as compared to vehicle control.
- PCP psychostimulant
- FIGURE 7 illustrates that Compound 34-1 of the present invention (Example 34) significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control.
- CAR conditioned avoidance response
- FIGURE 8 illustrates that Compound 36-1 of the present invention (Example 36) significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control.
- CAR conditioned avoidance response
- FIGURE 9 illustrates that Compound 47-1 of the present invention (Example 47) significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control.
- CAR conditioned avoidance response
- FIGURE 10 illustrates that Compound 61-1 of the present invention (Example 61) significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control.
- CAR conditioned avoidance response
- FIGURE 11 illustrates that Compound 63-1 of the present invention
- Example 63 significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control.
- CAR conditioned avoidance response
- FIGURE 12 illustrates that Compound 49-1 of the present invention (Example 49) significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control.
- CAR conditioned avoidance response
- FIGURE 13 illustrates that Compound 65-10 of the present invention (Example 65, Table 1) significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control.
- CAR conditioned avoidance response
- the present invention is directed generally to compounds useful as PDEIO inhibitors, as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.
- the PDEIO inhibitors have the following structure
- A is:
- Ri is Ci- 6 alkyl, Ci.ehaloalkyl, Ci ⁇ aialkyl, aryl, -(CH 2 ) contend0(CH 2 ) ffl CH 3 or -(CH 2 ) obligeN(CH 3 ) 2 ;
- R 2 is (i) substituted or unsubstituted aryl or (ii) substituted or unsubstituted heterocyclyl;
- R3 is substituted or unsubstituted aryl
- R4 is hydrogen, C ⁇ alkyl or C ⁇ haloalkyl
- n 1, 2, 3, 4, 5 or 6;
- n 0, 1, 2, 3, 4, 5 or 6.
- Amino refers to the -N3 ⁇ 4 radical.
- 'Nitro refers to the -NO2 radical.
- 'Ci.6alkyl means a straight chain or branched, noncyclic or cyclic, unsaturated or saturated aliphatic hydrocarbon radical containing from 1 to 6 carbon atoms.
- Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n- butyl, n-pentyl, n-hexyl, and the like; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, fert-butyl, isopentyl, and the like.
- Representative saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl and cyclohexenyl, and the like.
- Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms (referred to as an "alkenyl” or “alkynyl”, respectively).
- Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3 -methyl- 1-butenyl, 2-methyl-2-butenyl, 2,3- dimethyl-2-butenyl, and the like; while representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butynyl, 2- butynyl, 1-pentynyl, 2-pentynyl, 3- methyl- 1 -butynyl, and the like.
- Ci-6alkylene or "Ci-ealkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, which is saturated or unsaturated ⁇ i.e., contains one or more double and/or triple bonds), and having from one to six carbon atoms, e.g., methylene, ethylene, propylene, w-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like.
- the alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond.
- the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain.
- Ci- 6 alkoxy refers to a radical of the formula -OR a where R a is an alkyl radical as defined above, for example, methoxy, ethoxy and the like.
- Aryl means a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring.
- the aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems.
- Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
- Ci_ 6 aralkyl means a radical of the formula -Rt,-Rc where R b is an alkylene chain as defined above and c is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like.
- Cycloalkyl or “carbocyclic ring” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
- Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
- Halo or halogen refers to bromo, chloro, fluoro or iodo.
- Ci-6haloalkyl refers to a Ci- 6 alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.
- Heterocycle or “heterocyclyl” means a 4- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring.
- the heterocycle may be attached via any heteroatom or carbon atom.
- An aromatic heterocycle is referred to herein as a "heteroaryl", and includes (but is not limited to) furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, oxadiazolyl, thiadiazolyl, benzisoxazolyl, triazolyl, tetrazolyl, indazolyl and quina
- heterocycles also include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, and the like.
- heterocycles also include benzothiophen-2-yl, 2,3-dihydrobenzo-l,4-dioxin-6- yl, benzo-l,3-dioxol-5-yl and the like.
- substituted as used herein (for example, in the context of a substituted heterocyclyl or substituted aryl) means that at least one hydrogen atom is replaced with a substituent.
- the compound has the following structure (I- A):
- the compound has the following structure (I-B):
- the compound has the following structure (I-C):
- the compound has the following structure (I-D):
- the compound has the following structure (I-F):
- the compound has the following structure (I-G):
- the compound has the following structure (I-H):
- structures (I-1) in particular, structures (I-1)
- R4 is hydrogen or R4 is Chalky! (such as, for example, methyl).
- Ri is Ci ⁇ alkyl (such as, for example, Ri is methyl or ethyl).
- R3 is substituted or unsubstituted phenyl (such as, for example, 4-bromo-3,5-dimethoxyphenyl, 4-chloro- 3,5-dimethoxyphenyl or 3,4,5-trimethoxyphenyl).
- R2 is substituted or unsubstituted aryl, such as substituted or unsubstituted phenyl.
- R2 is phenyl substituted with Q. ealkoxy, or R2 is phenyl substituted with substituted or unsubstituted heterocyclyl (such as, for example, 4-(5-methyl-l,3,4-oxadiazol-2-yl)phenyl, 4-(5-methyl-l,3,4-thiadiazol- 2-yl)phenyl or 4-morpholinophenyl).
- the compounds of the present invention may generally be utilized as the free acid or free base. Alternatively, the compounds of this invention may be used in the form of acid or base addition salts. Acid addition salts of the free amino compounds of the present invention may be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, acetic, trifluoroacetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids.
- Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids.
- Base addition salts included those salts that form with the carboxylate anion and include salts formed with organic and inorganic cations such as those chosen from the alkali and alkaline earth metals (for example, lithium, sodium, potassium, magnesium, barium and calcium), as well as the ammonium ion and substituted derivatives thereof (for example, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, and the like).
- the term "pharmaceutically acceptable salt" of structure (I) is intended to encompass any and all acceptable salt forms.
- prodrugs are also included within the context of this invention.
- Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient.
- Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound.
- Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups.
- prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of structure (I).
- esters may be employed, such as methyl esters, ethyl esters, and the like.
- the invention disclosed herein is also meant to encompass all pharmaceutically acceptable compounds of structure (I) being isotopically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number.
- isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, n C, 13 C, 1 C, 13 N, 15 N, 15 0, n O, 18 0, 31 P, 32 P, 35 S, 18 F, 36 C1, 123 I, and 125 I, respectively.
- radiolabelled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action, or binding affinity to pharmacologically important site of action.
- Certain isotopically-labelled compounds of structure (I) for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
- the radioactive isotopes tritium, i.e. 3 H, and carbon- 14, i.e. 1 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- Substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Isotopically-labeled compounds of structure (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- the compounds of structure (I) may have chiral centers and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof. Furthermore, some of the crystalline forms of the compounds of structure (I) may exist as polymorphs, which are included in the present invention. In addition, some of the compounds of structure (I) may also form solvates with water or other organic solvents. Such solvates are similarly included within the scope of this invention.
- compositions containing one or more compounds of structure (I) are disclosed.
- the compounds of the present invention may be formulated as pharmaceutical compositions.
- Pharmaceutical compositions of the present invention comprise one or more compounds of the present invention and a pharmaceutically acceptable carrier and/or diluent.
- the PDE10 inhibitor is present in the composition in an amount which is effective to treat a particular disorder—that is, in an amount sufficient to achieve desired PDE10 inhibition, and preferably with acceptable toxicity to the warm-blooded animal.
- the pharmaceutical compositions of the present invention may include a PDE10 inhibitor in an amount from 0.1 mg to 250 mg per dosage depending upon the route of administration, and more typically from 1 mg to 60 rag. Appropriate concentrations and dosages can be readily determined by one skilled in the art.
- a typical daily dosage might range from about 1 ⁇ g kg to 100 mg/kg, preferably 0.01-100 mg/kg, more preferably 0.1-70 mg/kg, depending on the type and severity of the disease whether, for example, by one or more separate administrations. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs.
- other dosage regimens may be useful. The progress of this therapy can be monitored by standard techniques and assays.
- the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
- compositions formulated as liquid solutions include saline and sterile water, and may optionally include antioxidants, buffers, bacteriostats and other common additives.
- the compositions can also be formulated as pills, capsules, granules, or tablets which contain, in addition to a PDE10 inhibitor, diluents, dispersing and surface active agents, binders, and lubricants.
- PDE10 inhibitor in an appropriate manner, and in accordance with accepted practices, such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton, PA 1990.
- the present invention provides a method for treating diseases such as (but not limited to) psychotic disorders, anxiety disorders, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, bipolar disorders, post-traumatic stress disorders, drug-induced psychosis, panic disorders, obsessive-compulsive disorders, attention-deficit disorders, disruptive behavior disorders, autism, depression, dementia, cognitive disorders, epilepsy, insomnias and multiple sclerosis as discussed above.
- diseases such as (but not limited to) psychotic disorders, anxiety disorders, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia
- Such methods include administering of a compound of the present invention to a warm-blooded animal in an amount sufficient to treat the condition.
- "treat” includes prophylactic administration.
- Such methods include systemic administration of a PDE10 inhibitor of this invention, preferably in the form of a pharmaceutical composition as discussed above.
- systemic administration includes oral and parenteral methods of administration, including subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraarticular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, intravenous, intradermal, inhalational, transdermal, transmucosal, and rectal administration.
- suitable pharmaceutical compositions of PDE10 inhibitors include powders, granules, pills, tablets, and capsules as well as liquids, syrups, suspensions, and emulsions. These compositions may also include flavorants, preservatives, suspending, thickening and emulsifying agents, and other pharmaceutically acceptable additives and excipients.
- the compounds of the present invention can be prepared in aqueous injection solutions which may contain, in addition to the PDE10 inhibitor, buffers, antioxidants, bacteriostats, and other additives and excipients commonly employed in such solutions.
- compositions of the present invention may be carried in a delivery system to provide for sustained release or enhanced uptake or activity of the therapeutic compound, such as a liposomal or hydrogel system for injection, a microparticle, nanopartical or micelle system for oral or parenteral delivery, or a staged capsule system for oral delivery.
- a delivery system to provide for sustained release or enhanced uptake or activity of the therapeutic compound, such as a liposomal or hydrogel system for injection, a microparticle, nanopartical or micelle system for oral or parenteral delivery, or a staged capsule system for oral delivery.
- compounds of structure (I) are expected to avoid or reduce metabolic side effects associated with conventional antipsychotics, in particular the incidence of therapeutically induced obesity.
- conventional antipsychotics in particular the incidence of therapeutically induced obesity.
- olanzapine Zaprexa®
- the most widely prescribed medication to treat schizophrenia, and related atypical antipsychotics is associated with significant metabolic side effects including obesity and associated conditions such as diabetes;
- olanzapine In animals, subchronic treatment with olanzapine stimulates food intake and increases body weight, consistent with human situations. Furthermore, olanzapine acutely lowers blood leptin levels. Leptin is a satiety hormone produced from adipose tissues, and decrease of leptin level stimulates appetite. It is theorized that olanzapine could stimulate food intake at least partly by reducing leptin levels. Acute administration of olanzapine also changes the animal's response in glucose and insulin levels in glucose tolerance tests, which may also be directly linked to olanzapine's effect in food intake and body weight gain.
- compositions of the present invention may be administered in combination with one or more additional therapeutic agents, in combination or by concurrent or sequential administration.
- additional agents i.e. , adjuvants
- Compounds of this invention may be assayed to determine their IC50 values by a modification of the two-step method of Thompson and Appleman (Biochemistry 10; 311-316; 1971).
- cAMP is spiked with ( 3 H)cAMP and incubated with PDE10 and various concentrations of a compound of structure (I). After the appropriate incubation time, the reaction is terminated by heating. The mixture is then subjected to treatment with snake venom phosphatase. The phosphatase hydrolyzes any AMP in the mixture, but leaves unreacted cAMP intact.
- the percent of inhibition can be determined.
- IC50 values can be calculated by performing the experiment at several concentrations using standard graphical means. A detailed description of the actual technique used for IC50 assays as set forth in following Examples. To this end, PDE10 inhibitors of the invention have an IC50 of ⁇ or less, generally less than 10 ⁇ , and typically less than 1 ⁇ .
- the compounds of the present invention may be prepared by known organic synthesis techniques, including the methods described in more detail in the following examples. The following examples are provided for purposes of illustration, not limitation.
- the reaction flask was fitted with a reflux condenser, put under a drying tube and refluxed for 3 hours then cooled to room temp. After stirring overnight, the mixture was made basic with the addition of an aqueous solution of 2 M Na2CC>3, diluted with H2O then extracted with EtOAc three times. The combined organics were washed with brine, dried over Na2SC>4 and concentrated. The crude solid was dissolved in CH2CI2 and adsorbed onto silica gel. Purification by chromatography (0-35% EtOAc-hexanes) gave 4-(4-bromo-3,5-dimethoxyphenyl)thiazole as a white solid (0.20 g, 73% yield).
- Example 3 The method used for the final coupling step of Example 3 was used with modification. The reaction was allowed to warm to room temperature overnight. Purification by chromatography (40-55% EtOAc-hexanes) provided l-(4-(4-bromo-3,5- dimethoxyphenyl)- 1 -methyl- l/ -imidazol-2-yl)-2-methoxy-2-(4-morpholinophenyl) ethanone (0.0039 g, 4% yield). MS: m/z 530.1 [M+H] + .
- iV,2-dimethoxy-iV-methyl-2-(4-(pyrrolidin- 1 -yl)phenyl)acetamide was synthesized from 4-(pyrrolidin-l-yl)benzaldehyde following the method used for the synthesis of Example 1.
- A',2-dimethoxy-W-methyl-2-(quinolin-5-yl)acetamide was synthesized from quinoline-5-carbaldehyde in two steps following the method used for the synthesis of Example 1.
- l-(4-(4-Bromo-3,5-dimethoxyphenyl)oxazol-2-yl)-2-methoxy-2- (quinolin-5-yl)ethanone was synthesized from V,2-dimethoxy-JV-methyl-2-(quinolin-5- yl)acetamide and 4-(4-bromo-3,5-dimethoxyphenyl)oxazole following the method used for Example 2.
- Example 12 The method used for the final coupling step of Example 12 was used. Purification by chromatography (20-55% EtOAc-hexanes) provided 2-(4-(li/-pyrazol- l-yl)phenyl)-l-(5-(4-bromo-3,5-dimethoxyphenyl)furan-2-yl)-2-methoxyethanone as a light yellow solid (0.0625 g, 37% yield). MS: m/z 497.2 [M+H] + .
- Example 1 The method used for the synthesis of Example 1 was used except that the potassium salt was isolated. Following the reaction at room temperature, EtOAc was added and the mixture was filtered through Celite and concentrated in vacuo. The residue was dissolved in EtOAc, filtered through Celite and concentrated in vacuo. The product was dissolved in EtOAc-toluene and concentrated to give potassium 2- methoxy-2-(4-(l-(tris(4-methoxyphenyl)methyl)-l//-pyrazol-4-yl)phenyl)acetate (1.75 g, quantitative yield) which was used without further purification.
- Example 12 The method used for the final coupling step of Example 12 was used except with a shorter reaction time at room temperature of 70 min. Purification by chromatography (35-90% EtOAc-hexanes; EtOAc containing 1% Et3N) provided l-(5- (4-bromo-3,5-mmemoxyphenyl)furan-2-yl)-2-methoxy-2-(4-(l-(tris(4- memoxyphenyl)methyl)-l//-pyrazol-4-yl)phenyl)ethanone as a solid (0.10 g, 18% yield).
- a ⁇ ,2-Dimemoxy-Af-memyl-2-(4-(5-methylfuran-2-yl)phenyl)acetamide was synthesized from 2-methoxy-2-(4-(5-methylfuran-2-yl)phenyl)acetic acid following the method used for Example 13. The product was isolated as an orange oil (0.693 g, 18% yield).
- Example 12 The method used for the final coupling step of Example 12 was followed for the reaction of 5-(furan-2-yl)-2,3-dimethoxybenzonitrile and iV,2-dimethoxy-Af- methyl-2-(4-(5-methyl-l,3,4-oxadiazol-2-yl)phenyl)acetamide except that the reaction was performed at -40 to -25 °C then warmed to room temperature.
- Example 1 The method used for the synthesis of Example 1 was followed for the synthesis of 2-(4-(5-ethyl-l,3,4-oxadiazol-2-yl)phenyl)-JV,2-dimethoxy-A' ' - methylacetamide from 2-(4-(5-ethyl-l,3,4-oxadiazol-2-yl)phenyl)-2-methoxyacetic acid.
- Example 12 The method used for the final coupling step of Example 12 was followed for the reaction of 2-(4-bromo-3,5-dimethoxyphenyl)furan with 2-(4-(5-ethyl-l,3,4- oxadiazoI-2-yl)phenyl)-iV,2-dimethoxy-A'-methylacetamide.
- Example 1 The method used for the synthesis of Example 1 was followed for the synthesis of 2-methoxy-2-(4-nitrophenyl)acetic acid from 4-nitrobenzaldehyde. The acid isolated after aqueous extraction was used without further purification (5.3 g, 76% yield).
- 2,2,2-TrichIoro-l -(4-(5-cyclopropyl-l ,3 ,4-oxadiazol-2-yl)phenyl)ethanol was synthesized from 4-(5-cyclopropyl-l,3 > 4-oxadiazol-2-yl)benzaldehyde according to the procedure for the synthesis of Example 18.
- the product was isolated as a white solid and used without further purification (2.5 g, 89% yield).
- 2-Methoxy-2-(6-(piperidin-l-yl)pyridin-3-yl)acetic acid was synthesized from 6-(piperidin-l-yl)nicotinaldehyde according to the procedure used for the synthesis of Example 1 except that the reaction mixture was cooled over ice before the addition of KOH-MeOH solution. The product was isolated as a light beige foam and was used without further purification (0.569 g, 52% yield).
- 2-Methoxy-2-(4-(morpholinomethyl)phenyl)acetic acid was synthesized from 4-(morpholinomethyl)benzaldehyde following the procedure for the synthesis of Example 23. Following the reaction, the volatiles were removed in vacuo. The residue was redissolved in a minimum amount of H 2 0 and acidified with 1 M HC1 to pH 3. The aqueous layer was concentrated in vacuo and the residue was suspended in MeOH and sonicated and warmed slightly. The mixture was filtered through Celite and concentrated in vacuo to give a white solid (3 g, quant, yield). The product was taken on to the next synthetic step without purification.
- iV,2-Dimethoxy- V-methyl-2-(4-(morpholinomethyl)phenyl)acetamide was synthesized from 2-methoxy-2-(4-(morpholinomethyl)phenyl)acetic acid following the procedure used for Example 13. Purification by chromatography (0-7% N3 ⁇ 4- MeOH solution in CH 2 C1 2 ; 0.7 M NH 3 -MeOH) gave N,2-dimethoxy-W-methyl-2-(4- (morpholinomethyl)phenyl)acetamide as an orange oil (0.743 g, 41% yield).
- 2-(4-(l i-l,2,3-Triazol-l-yl)phenyl)-2-methoxyacetic acid was prepared from 4-(l -l,2,3-triazol-l-yl)benzaldehyde according to the procedure used in Example 30. The product was obtained as an oil and used without further purification (1.02 g, 76% yield).
- 2-(4-(l//-l,2,4-Triazol-l-yl)phenyl)-2-methoxyacetic acid was prepared from 4-(l//-l,2,4-triazol-l-yl)benzaldehyde according to the procedure used in Example 30.
- the crude product was obtained as a white solid and used without further purification (1.9 g, 47% yield).
- 2-Methoxy-2-(4-(2-methyl-2//-tetrazol-5-yl)phenyl)acetic acid was prepared from 4-(2-methyl-2i7-tetrazol-5-yl)benzaldehyde according to the procedure used in Example 30.
- the crude product was obtained as an oil and used without further purification (0.88 g, 86% yield).
- 2-Methoxy-2-(4-(5-methyl-l ,3,4-thiadiazol-2-yl)phenyl)acetic acid was prepared from 4-(5-methyl-l,3,4-thiadiazol-2-yl)benzaldehyde according to the procedure used in Example 30.
- the crude product was obtained as an oil and used without further purification (1.12 g, 75% yield).
- 3 ⁇ 42-Dimethoxy-Af-me l-2-(4 5-memyl-l,3,4-thiadiazol-2- yl)phenyl)acetamide was prepared from 2-methoxy-2-(4-(5-methyl-l,3,4-thiadiazol-2- yl)phenyl)acetic acid according to the procedure used in Example 33. Purification by chromatography (100% EtOAc) gave the product as a pale yellow oil (0.177 g, 26% yield).
- 2-Methoxy-2-(4-(2-methylthiazol-4-yl)phenyl)acetic acid was prepared from 4-(2-methylmiazol-4-yl)benzaldehyde according to the procedure used in Example 30.
- the crude product was obtained as an oil and used without further purification (0.972 g, 78% yield).
- Af,2-Dimemoxy-A'-memyl-2-(4-(2-methylthiazol-4-yl)phenyl)acetamide was prepared from 2-methoxy-2-(4-(2-methylthiazol-4-yl)phenyl)acetic acid according to the procedure used in Example 33. Purification by chromatography (70% EtOAc hexanes) gave the product as an oil (0.516 g, 46% yield).
- 2-(3,4,5-Trimethoxyphenyl)furan was prepared from 5-iodo-l,2,3- trimethoxybenzene according to the procedure used in Example 12. Purification by chromatography (10% EtOAc/hexanes) gave the product as an off white solid (1.2 g, 60% yield).
- 2-Methoxy-2-(4-(pyridin-3-yl)phenyl)acetic acid was prepared from 4- (pyridin-3-yl)benzaldehyde according to the procedure used in Example 30 except pH 4 was used during the extractive work-up.
- the crude product was obtained as an oil and used without further purification (0.415 g, 33% yield).
- iV,2-Dimethoxy-iV-methyl-2-(4-(pyridin-3-yl)phenyl)acetamide was prepared from 2-methoxy-2-(4-(pyridin-3-yl)phenyl)acetic acid according to the procedure used in Example 33. Purification by chromatography (100% EtOAc) gave the product as an oil (0.232 g, 48% yield.
- 2-Ethoxy-2-(4-morpholinophenyl)acetic acid was synthesized from 4- morpholinobenzaldehyde according to the procedure used for the synthesis of Example 1 except that EtOH was used as the solvent. The product was isolated as a pale red oil and used without further purification.
- 2-Ethoxy-iV-methoxy-W-methyl-2-(4-morpholinophenyl)acetami was synthesized from 2-ethoxy-2-(4-morpholinophenyl)acetic acid following the procedure used for Example 13. Purification by chromatography (EtOAc-hexanes) provided the product as a yellow solid (1.0 g, 31% yield for two steps).
- 3-Bromo-4,5-dimethoxyphenyl trifluoromethanesulfonate was prepared from 3-bromo-4,5-dimethoxyphenol according to the procedure used in Example 21. Evaporation to dryness gave the product as a pale yellow oil (3.3 g, 100% yield).
- 2-(3-Bromo-4,5-dimethoxyphenyl)furan was prepared from 3-bromo- 4,5-dimethoxyphenyl trifluoromethanesulfonate according to the procedure used in Example 21. Purification by chromatography (10% ether/hexanes) gave the product as a pale yellow oil (1.7 g, 73% yield).
- 3-Chloro-4,5-dimethoxyphenol was synthesized from 3-chloro-4,5- dimethoxybenzaldehyde according to the procedure used for the synthesis of Example 21.
- the crude solid obtained was digested with -10% EtOAc-hexanes at 40 °C for 1 hr. After cooling to room temperature, the solid was collected on a Biichner and dried in vacuo to give a crystalline beige solid (1.44 g, 38% yield for two steps).
- 3-Chloro-4,5-dimethoxyphenyl trifluoromethanesulfonate was synthesized from 3-chloro-4,5-dimethoxyphenol according to the procedure for the synthesis of Example 21.
- the product was isolated as a pale yellow liquid and used in the next synthetic step without further purification (2.33 g, 96% yield).
- 2-(3-Chloro-4,5-dimemoxyphenyl)furan was synthesized from 3-chloro- 4,5-dimethoxyphenyl triflupromethanesulfonate according to the procedure used in the synthesis of Example 21. Purification by chromatography (10% Et20-hexanes) gave the product as a pale yellow oil (1.6 g, 94% yield).
- 2-Methoxy-2-(6-methoxypyridin-3-yl)acetic acid was prepared from 6- methoxynicotinaldehyde according to the procedure used in Example 37. The crude product was obtained as an oil and used without further purification (5.67 g, 79% yield).
- Af,2-Dimethoxy-2-(6-methoxypyridin-3-yl)-i ⁇ i'-methylacetamide was prepared from 2-methoxy-2-(6-methoxypyridin-3-yl)acetic acid according to the procedure used in Example 33. Purification by chromatography (60% EtOAc/hexanes) gave the product as an oil (0.97 g, 40% yield).
- 2-(4-((Dimethylamino)methyl)phenyl)-2-methoxyacetic acid was prepared from 4-((dimethylamino)methyl)benzaldehyde according to the procedure used in Example 37. After the pH was adjusted to 4 the aqueous solution was evaporated to dryness. MeOH (20 ml) was added with swirling and the material was filtered. Evaporation to dryness gave the crude product that was used without further purification (1.3 g, 95% yield).
- 2-Methoxy-2-(6-morpholinopyridin-3-yl)acetic acid was prepared from 6-morpholinonicotinaldehyde according to the procedure used in Example 30 except the aqueous mixture was adjusted to pH 4 during the extractive work-up. The crude product was obtained as an oil and used without further purification (1.17 g, 89% yield).
- a f ,2-Dimethoxy-JV-methyl-2-(6-rnorpholinopyridin-3-yl)acetamide was prepared from 2-methoxy-2-(6-morpholinopyridin-3-yl)acetic acid according to the procedure used in Example 33. Purification by chromatography (80% EtOAc hexanes) gave the product as an oil (0.692 g, 51% yield).
- 2-Methoxy-2-(4-(pyrazin-2-yl)phenyl)acetic acid was prepared from 4- (pyrazin-2-yl)benzaldehyde according to the procedure used in Example 30 except the aqueous mixture was adjusted to pH 4 during the extractive work-up. The crude product was obtained as an oil and was used without further purification (1.21 g, 91% yield).
- a ⁇ ,2-Dimethoxy-Af-methyl-2-(4-(pyrazin-2-yl)phenyl)acetamide was prepared from 2-methoxy-2-(4-(pyrazin-2-yl)phenyl)acetic acid according to the procedure used in Example 33. Purification by chromatography (80% EtOAc/hexanes) gave the product as an oil (0.493 g, 35% yield).
- 2-(4-Fluoro-3,5-dimethoxyphenyl)furan was prepared from 5-bromo-2- fluoro-l,3-dimethoxybenzene (US6177154 Bl) according to the procedure used in Example 15. Purification by chromatography (10% EtOAc/hexanes) gave the product as a white solid (2.1 g, 58% yield).
- This synthetic intermediate was dissolved in anhydr DMF (15 mL) under argon then heated at 120 °C for 7 hrs. After cooling to room temp, the reaction was diluted with 3 ⁇ 40 and extracted with EtOAc. The combined organics were washed with 3 ⁇ 40 and brine, dried over Na2SC>4 and concentrated in vacuo.
- 2-(4-Bromo-3,5-dimethoxyphenyl)thiophene was prepared from 2- bromo-5-iodo-l,3-dimethoxybenzene and thiophen-2-ylboronic acid according to the procedure used in Example 12. Purification by chromatography (0-10% EtOAc- hexanes) gave a yellow solid (0.624 g, 55% yield).
- the phosphodiesterase (PDE) assay was performed using recombinant human PDE 1 A3, 2 A3, 3 catalytic region, 4 catalytic region, 5 catalytic region, 7 A, 8 A, 9A2, 10A1 and 11A1 enzymes expressed in a baculoviral system using Sf9 cells.
- PDE activity was measured using a modification of the two-step method of Thompson and Appleman described above which was adapted for 96 well plate format.
- the effect of the PDE inhibitors was determined by assaying a fixed amount of the enzyme in the presence of test compound concentrations and a substrate concentration below that of the Km, so that Ki equals IC50.
- the final assay volume was 110 ⁇ with assay buffer (lOmM MgC3 ⁇ 4; 40mM Tris.HCl; pH 7.4). Reactions were initiated with enzyme and incubated with ( 3 H) -substrate and substance for 20 minutes at 30 °C. The reaction was terminated by denaturing the enzyme (heating the reaction to 70 °C for 2 minutes). The reaction was then cooled at 4 °C for 10 minutes before the addition of snake venom (Crotalus atrox, 0.2 mg/ml) for 10 minutes at 30 °C, thus allowing non-specific hydrolysis of the tritiated substrate.
- assay buffer assay buffer
- assay buffer assay buffer
- Reactions were initiated with enzyme and incubated with ( 3 H) -substrate and substance for 20 minutes at 30 °C. The reaction was terminated by denaturing the enzyme (heating the reaction to 70 °C for 2 minutes). The reaction was then cooled at 4 °C for 10 minutes before the addition of snake
- Separation of the remaining unhydrolysed cyclic nucleotide was achieved by a batch binding of the mixture to activated Dowex (200 ⁇ ) anion exchange resin.
- the anion exchange resin bound the charged nucleotides, leaving only hydrolysed ( 3 H) substrate in the soluble fraction.
- the soluble fraction (50 ⁇ ) was then added to microscint-20 (200 ⁇ ) and counted on a Top Count Plate reader. Radioactivity units were plotted against inhibitor concentration and IC50 values obtained using Graph Pad Prism software.
- phosphodiesterase activity was measured by scintillation proximity assay (SPA) with [ 3 H] - cGMP as substrate.
- Purified PDE10 was diluted and stored in 25 mM Tris-Cl (pH 8.0)/100 mM NaCl/0.05% Tween 20/50% glycerol/3 mM DTT.
- Assays contained (final concentrations): 50 mM Tris-Cl (pH 7.5)/8.3 mM MgCl 2 /l .7 mM EGTA/0.5 mg/ml BSA/5% DMSO and 2 ng PDE10 in a final volume of 0.1 mL. Inhibition was evaluated at 8 concentrations in duplicate.
- the inhibition of other PDE enzymes by the PDE10 inhibitors was evaluated under the same conditions described above for PDE10 except the amount of enzyme added was optimized for each PDE. Fractional inhibition was evaluated at four concentrations (0.1, 1, 10, and 100 ⁇ ). In cases where inhibition at the highest concentration was less than 50%, the lower limit value in the logistic model was fixed to 0% activity.
- compounds of this invention are PDE10 inhibitors with an IC50 of ⁇ or less, generally less than 10 ⁇ , and typically less than 1 ⁇ .
- Known antipsychotic drugs including both typical antipsychotics (e.g., haloperidol) and atypical antipsychotics (e.g., olanzapine), reverse such psychotomimetic states in animals.
- Examples 67-77 described below evaluate representative compounds of the present invention in animal behavioral models to allow comparison of the resulting effect to that of known antipsychotics. Methods used in the Examples 67-77 are as follows.
- Dosing of the compounds is by intraperitoneal (i.p.) injection or oral gavage (p.o.).
- Intraperitoneal injection is accomplished by restraining the animal, exposing the abdomen and inserting the needle just above the knees on the mouse's right side.
- Oral gavage is performed by restraining the animal in such a way that its head is tilted back and the esophagus is relatively straight.
- the gavage needle (20G x 1.5", Cadence Science) is inserted into the mouth in line with the body and gently pushed along the esophagus and into the stomach. If resistance is encountered the needle is removed and reinserted.
- Psychiamic hyperactivity is measured by injecting animals with PCP and monitoring the animals' activity levels in VersaMax chambers (Accuscan Instruments, Columbus, OH) measuring 40 x 40 cm. Locomotor activity is detected by photobeam breaks as the animal crosses each beam. The animal is placed in the center of the field and left undisturbed for 20 minutes to measure its spontaneous activity in a novel environment. Measurements used to assess locomotor activity include: horizontal activity, total distance traveled, vertical activity (rearing events - animal raises up on hindlimbs), rotation, stereotypy, and distance traveled in the center compared to total distance traveled (center: total distance ratio).
- the NMDA antagonist PCP induces a pychosis-like syndrome manifest as hyperactivity and increased stereotypic behavior.
- Known antipsychotics are able to reverse psychostimulant-induced hyperactivity and stereotypy.
- Conditioned avoidance response is a behavioral test to evaluate the antipsychotic effect of a test compound. It utilizes a shuttle box (Med Associates, St. Albans, VT) with two identical chambers separated by a retractable door. Each chamber is fitted with a metal grid floor that is capable of delivering electric shocks independently.
- a computer program is used to implement the testing paradigm as well as record the animal's movement between the two chambers through infrared beam sensors.
- the testing paradigm is as follows. A mouse is placed into one chamber. A light (conditioned stimulus, CS) comes on.
- Compound 1-1 (Example 1) was found to reduce PCP-induced hyperactivity, as shown in FIGURES 1 and 2.
- C57BL/6 male mice were given either compound 1-1 or vehicle by intraperitoneal injection (FIGURE 1) or oral gavage (FIGURE 2). Twenty minutes (for i.p.) or forty minutes (for p.o.) later, they were injected with PCP (5 mg kg, i.p.). Ten minutes later, the mice were placed in activity chambers and their locomotor activity in the horizontal dimension was monitored by infrared beam breaks for 20 min (5 consecutive 4-minute intervals (INT) as indicated).
- INT 4-minute intervals
- Compound 2-1 (Example 2) was found to reduce PCP-induced hyperactivity, as shown in FIGURES 3 and 4.
- C57BL/6 male mice were given either compound 2-1 or vehicle by intraperitoneal injection (FIGURE 3) or oral gavage (FIGURE 4). Twenty minutes (for i.p.) or 40 minutes (for p.o.) later, they were injected with PCP (5 mg/kg, i.p.). Ten minutes later, the mice were placed in activity chambers and their locomotor activity in the horizontal dimension was monitored by infrared beam breaks for 20 min (5 consecutive 4-minute intervals (INT) as indicated).
- INT 4-minute intervals
- Avoidance Responses CAR
- CAR Avoidance Responses
- C57BL/6 male mice were trained in the CAR paradigm to predict and avoid the noxious stimulus (foot shock), reaching a plateau of approximately 25 avoidance responses per 30 trials each day.
- the mice were then given either vehicle or compound 2-1 via oral gavage, 30 minutes before testing for 30 trials in the CAR paradigm.
- Vehicle treatment and compound treatment were given to the same animals on alternating days, and the effect of compound in reducing avoidance response was analyzed through within-subject comparison (paired t-test). Vehicle exposure does not alter the avoidance response of these trained animals.
- Compound 11-1 (Example 11) was found to reduce PCP-induced hyperactivity, as shown in FIGURE 6.
- C57BL/6 male mice were given either compound 11-1 or vehicle by intraperitoneal injection. Five minutes later they were injected with PCP (5 mg/kg, i.p.). Ten minutes later, the mice were placed in activity chambers and their locomotor activity in the horizontal dimension was monitored by infrared beam breaks for 20 min (5 consecutive 4-minute intervals (INT) as indicated).
- Compound 34-1 (Example 34) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 7.
- CAR Conditioned Avoidance Responses
- Compound 47-1 (Example 47) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 9.
- CAR Conditioned Avoidance Responses
- CAR Conditioned Avoidance Responses
- FIGURE 9 C57BL/6 male mice were trained in the CAR paradigm to predict and avoid the noxious stimulus (foot shock), reaching a plateau of approximately 25-28 avoidance responses per 30 trials ("training plateau") each day. The mice were then given either vehicle or compound (55 minutes prior to testing) via oral gavage, and then were tested for 30 trials in the CAR paradigm. Vehicle treatment and compound treatment were given to the same animals on alternating days, and the effect of compound in reducing avoidance response was analyzed through within-subject comparison (paired t-test). Vehicle exposure (“vehicle”) does not alter the avoidance response of these trained animals.
- Avoidance Responses CAR
- CAR Avoidance Responses
- C57BL/6 male mice were trained in the CAR paradigm to predict and avoid the noxious stimulus (foot shock), reaching a plateau of approximately 25-28 avoidance responses per 30 trials ("training plateau") each day.
- the mice were then given either vehicle or compound (55 minutes prior to testing) via oral gavage, and then were tested for 30 trials in the CAR paradigm.
- Vehicle treatment and compound treatment were given to the same animals on alternating days, and the effect of compound in reducing avoidance response was analyzed through within-subject comparison (paired t-test). Vehicle exposure (“vehicle”) does not alter the avoidance response of these trained animals.
- Compound 63-1 (Example 63) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 11.
- CAR Conditioned Avoidance Responses
- CAR Conditioned Avoidance Responses
- Compound 49-1 (Example 49) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 12.
- CAR Conditioned Avoidance Responses
- CAR Conditioned Avoidance Responses
- Compound 65-10 (Example 65, Table 1) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 13.
- CAR Conditioned Avoidance Responses
- CAR Conditioned Avoidance Responses
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK11754087.2T DK2544679T3 (en) | 2010-03-12 | 2011-03-10 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND PROCEDURES |
NZ60196711A NZ601967A (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods |
KR1020177005754A KR101846136B1 (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods |
KR1020127026545A KR101512548B1 (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods |
KR1020157000406A KR101713453B1 (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods |
AU2011224287A AU2011224287B2 (en) | 2010-03-12 | 2011-03-10 | PDE10 inhibitors and related compositions and methods |
JP2012557252A JP5674828B2 (en) | 2010-03-12 | 2011-03-10 | PDE10 inhibitors and related compositions and methods |
CN201180012372.0A CN102869355B (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods |
MX2012010400A MX339950B (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods. |
KR1020157000405A KR101713452B1 (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods |
PL11754087T PL2544679T3 (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods |
EP11754087.2A EP2544679B1 (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods |
BR112012022910-9A BR112012022910B1 (en) | 2010-03-12 | 2011-03-10 | PDE10 INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING SUCH COMPOUNDS AND THEIR USE TO TREAT NEUROLOGICAL DISORDERS IN A HOT-BLOOD ANIMAL |
RU2012143610/04A RU2545456C2 (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and compositions containing them and methods |
ES11754087T ES2742195T3 (en) | 2010-03-12 | 2011-03-10 | PDE10 inhibitors and related compositions and methods |
CA2792844A CA2792844C (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods |
ZA2012/06718A ZA201206718B (en) | 2010-03-12 | 2012-09-07 | Pde10 inhibitors and related compositions and methods |
IL221906A IL221906B (en) | 2010-03-12 | 2012-09-11 | Pde10 inhibitor compounds, compositions comprising the same and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31354410P | 2010-03-12 | 2010-03-12 | |
US61/313,544 | 2010-03-12 | ||
US201161430841P | 2011-01-07 | 2011-01-07 | |
US61/430,841 | 2011-01-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011112828A1 true WO2011112828A1 (en) | 2011-09-15 |
Family
ID=44560551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/027927 WO2011112828A1 (en) | 2010-03-12 | 2011-03-10 | Pde10 inhibitors and related compositions and methods |
Country Status (19)
Country | Link |
---|---|
US (5) | US8343970B2 (en) |
EP (1) | EP2544679B1 (en) |
JP (2) | JP5674828B2 (en) |
KR (4) | KR101713453B1 (en) |
CN (3) | CN104710385B (en) |
AU (1) | AU2011224287B2 (en) |
BR (1) | BR112012022910B1 (en) |
CA (1) | CA2792844C (en) |
CL (1) | CL2012002506A1 (en) |
DK (1) | DK2544679T3 (en) |
ES (1) | ES2742195T3 (en) |
IL (1) | IL221906B (en) |
MX (1) | MX339950B (en) |
NZ (3) | NZ705058A (en) |
PL (1) | PL2544679T3 (en) |
PT (1) | PT2544679T (en) |
RU (1) | RU2545456C2 (en) |
WO (1) | WO2011112828A1 (en) |
ZA (1) | ZA201206718B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012112946A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
US8278327B2 (en) | 2006-11-21 | 2012-10-02 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US8685975B2 (en) | 2010-03-12 | 2014-04-01 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
JP2015521193A (en) * | 2012-05-31 | 2015-07-27 | フェネックス ファーマシューティカルス アーゲー | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators of the orphan nuclear receptor RORγ |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
US9493447B2 (en) | 2014-04-28 | 2016-11-15 | Omeros Corporation | Optically active PDE10 inhibitor |
US9650368B2 (en) | 2014-04-28 | 2017-05-16 | Omeros Corporation | Processes and intermediates for the preparation of a PDE10 inhibitor |
US9783521B2 (en) | 2008-08-05 | 2017-10-10 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US9879002B2 (en) | 2015-04-24 | 2018-01-30 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US9920045B2 (en) | 2015-11-04 | 2018-03-20 | Omeros Corporation | Solid state forms of a PDE10 inhibitor |
CN113272285A (en) * | 2018-09-21 | 2021-08-17 | 爱思开生物制药株式会社 | Oxadiazole-containing compound and pharmaceutical composition containing the same |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2480341B1 (en) | 2013-01-24 | 2015-01-22 | Palobiofarma S.L | New derivatives of pyrimidine as phosphodiesterase 10 (PDE-10) inhibitors |
WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
US10424374B2 (en) | 2017-04-28 | 2019-09-24 | Micron Technology, Inc. | Programming enhancement in self-selecting memory |
US10854813B2 (en) | 2018-02-09 | 2020-12-01 | Micron Technology, Inc. | Dopant-modulated etching for memory devices |
US10424730B2 (en) | 2018-02-09 | 2019-09-24 | Micron Technology, Inc. | Tapered memory cell profiles |
US10541364B2 (en) | 2018-02-09 | 2020-01-21 | Micron Technology, Inc. | Memory cells with asymmetrical electrode interfaces |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996000218A1 (en) | 1994-06-24 | 1996-01-04 | Euro-Celtique, S.A. | Compounds for and method of inhibiting phosphodiesterase iv |
US5693652A (en) | 1991-09-30 | 1997-12-02 | Eisai Co., Ltd. | Benzimidazoles for ischemic heart conditions |
US6177154B1 (en) | 1996-09-17 | 2001-01-23 | Chisso Corporation | Alkoxybenzene derivative, liquid-crystal composition, and liquid-crystal display element |
WO2001041807A2 (en) | 1999-12-10 | 2001-06-14 | Vivus, Inc. | Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6403805B1 (en) * | 1995-04-06 | 2002-06-11 | Janssen Pharmaceutica N.V. | 1,3-dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatves |
US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
EP1568691A1 (en) | 2002-12-06 | 2005-08-31 | Kowa Co., Ltd. | Erythropoietin production accelerator |
US20060128695A1 (en) | 2002-10-30 | 2006-06-15 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
US7129238B2 (en) | 2002-11-25 | 2006-10-31 | Hoffmann-La Roche Inc. | Mandelic acid derivatives |
WO2007073299A1 (en) | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Imidazoles as gaba-b receptor modulators |
WO2008040669A2 (en) | 2006-10-02 | 2008-04-10 | Janssen Pharmaceutica N.V. | Novel intermediates for the preparation of a glyt1 inhibitor |
US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
US20090221586A1 (en) * | 2005-11-15 | 2009-09-03 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound and pharmaceutical composition |
WO2010017236A1 (en) | 2008-08-05 | 2010-02-11 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK178590D0 (en) | 1990-07-26 | 1990-07-26 | Novo Nordisk As | 1,4-DISUBSTITUTED PIPERAZINES |
WO1994012461A1 (en) * | 1992-12-02 | 1994-06-09 | Pfizer Inc. | Catechol diethers as selective pdeiv inhibitors |
DE4323192A1 (en) * | 1993-07-10 | 1995-01-12 | Basf Ag | Process for the preparation of homopolymers and copolymers of alk-1-enes |
DE4325846C1 (en) | 1993-07-31 | 1995-01-19 | Herberts Gmbh | Use of furan-modified aromatic pinacol derivatives as initiators and furan-modified aromatic pinacol derivatives as such |
DE4343286A1 (en) | 1993-12-17 | 1995-06-22 | Hoechst Ag | Phthalzine cpds. used in liq. crystal mixt. to reduce memory angle |
DE4409501A1 (en) | 1994-03-19 | 1995-09-21 | Didier Werke Ag | Wear lining of a shaft furnace and stone therefor |
US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
TW424087B (en) | 1995-04-06 | 2001-03-01 | Janssen Pharmaceutica Nv | 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives |
US6037370A (en) | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
KR19990076788A (en) | 1996-01-22 | 1999-10-15 | 후지야마 아키라 | Thiazolylbenzofuran derivatives and pharmaceutical compositions containing the same |
AU4015497A (en) * | 1996-08-26 | 1998-03-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thiazole derivatives useful as selective inhibitors of pde-iv |
WO1999045914A1 (en) | 1998-03-13 | 1999-09-16 | Maruho Kabushikikaisha | Alkyl amine derivative and local anesthetic agent using the same |
GB9807354D0 (en) | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
SE9804212D0 (en) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
ATE278674T1 (en) | 1999-03-12 | 2004-10-15 | Boehringer Ingelheim Pharma | HETEROCYCLIC UREA AND RELATED COMPOUNDS AS ANTI-INFLAMMATORY AGENTS |
US7141593B1 (en) | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
GB9929552D0 (en) | 1999-12-14 | 2000-02-09 | Proteus Molecular Design | Compounds |
US7119098B2 (en) | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
NZ529118A (en) | 2001-05-22 | 2005-10-28 | Pfizer Prod Inc | Crystal forms of azithromycin |
US6821502B2 (en) | 2002-06-12 | 2004-11-23 | Chevron U.S.A. Inc. | Method of making aluminum-containing zeolite with IFR structure |
AU2003254481A1 (en) | 2002-07-27 | 2004-02-16 | Astrazeneca Ab | Chemical compounds |
EA008767B1 (en) | 2002-10-08 | 2007-08-31 | Зе Скрипс Ресеч Инститьют | Inhibitors of fatty acid amide hydrolase |
JP2006518333A (en) | 2002-12-20 | 2006-08-10 | ファルマシア・コーポレーション | Heteroarylalkanoic acids as integrin receptor antagonists |
WO2004071509A1 (en) | 2003-02-12 | 2004-08-26 | Nippon Chemiphar Co., Ltd. | Oligodendrocyte differentiation promoters |
KR20060005375A (en) | 2003-04-18 | 2006-01-17 | 메모리 파마슈티칼스 코포레이션 | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
AR047541A1 (en) | 2004-02-13 | 2006-01-25 | Sandoz Ag | PHOSPHATE OF 5 - [[4- [2-METHYL-2-PYRIDINYL-AMINO-ETOXI] PHENYL] METHYL] -2,4 THYZOLIDINADION (ROSIGLITAZONE) AND ITS POLYMORPHIC FORMS |
JP4879165B2 (en) | 2004-04-20 | 2012-02-22 | トランス テック ファーマ,インコーポレイテッド | Substituted thiazole and pyrimidine derivatives as modulators of melanocortin receptors |
US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
US7351833B2 (en) | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
US7449486B2 (en) * | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
US8436176B2 (en) | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
MX2007008287A (en) | 2005-01-07 | 2007-09-07 | Pfizer Prod Inc | Heteroaromatic quinoline compounds and their use as pde10 inhibitors. |
MY158077A (en) | 2005-02-04 | 2016-08-30 | Senomyx Inc | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers tastants and taste enhancers for comestible compositions |
EP1871770A1 (en) | 2005-04-22 | 2008-01-02 | Kalypsys, Inc. | Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders |
UA91546C2 (en) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
JP2009503107A (en) * | 2005-08-04 | 2009-01-29 | アポジー・バイオテクノロジー・コーポレイション | Sphingosine kinase inhibitors and methods for their use |
PT1924585E (en) | 2005-08-29 | 2012-01-19 | Sanofi Aventis Us Llc | Novel crystalline form of a pyridazino [4 , 5-b] indole derivative |
JP2008522983A (en) | 2005-09-13 | 2008-07-03 | シコール インコーポレイティド | Method for synthesizing rocuronium bromide |
WO2007129183A2 (en) * | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
ES2376493T3 (en) | 2006-09-08 | 2012-03-14 | Ore Pharmaceuticals Inc. | PROCEDURE TO REDUCE OR RELIEF INFLAMMATION IN THE DIGESTIVE TUBE. |
MX2009003160A (en) | 2006-09-25 | 2009-04-06 | Ptc Therapeutics Inc | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl] -benzoic acid. |
CN101528212A (en) | 2006-09-28 | 2009-09-09 | 默克公司 | Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitor chelate complexes |
US7837978B2 (en) | 2006-10-13 | 2010-11-23 | Chevron U.S.A. Inc. | Process for preparing aluminum-containing molecular sieve SSZ-26 |
EP2083819B1 (en) | 2006-11-21 | 2017-02-22 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
US7786139B2 (en) * | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
PE20081506A1 (en) | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | ANSAMYCIN FORMULATIONS |
WO2009008906A2 (en) * | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
WO2008143500A1 (en) | 2007-05-22 | 2008-11-27 | Ultimorphix Technologies B.V. | Tenofovir disoproxil hemi-fumaric acid co-crystal |
EP2017264A1 (en) | 2007-07-16 | 2009-01-21 | Bayer Cropscience Ag | Substituted phenyl propargyl compounds, method for their manufacture and their use as herbicides and plant growth regulators |
US20090186014A1 (en) | 2007-10-10 | 2009-07-23 | Ore Pharmaceuticals Inc. | Method for treatment of pancreatitis |
TW200944520A (en) | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
WO2009143178A2 (en) | 2008-05-20 | 2009-11-26 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
TWI501965B (en) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | Novel phenylimidazole derivatives as pde10a enzyme inhibitors |
WO2011068821A1 (en) * | 2009-12-04 | 2011-06-09 | Boehringer Ingelheim International Gmbh | Benzimidazole inhibitors of leukotriene production |
KR101713453B1 (en) | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 inhibitors and related compositions and methods |
EP2651766B1 (en) | 2010-12-16 | 2015-03-11 | Boehringer Ingelheim Microparts GmbH | Method for filling a cavity, in particular a blister of a blister packaging, with a liquid |
NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
NZ630810A (en) * | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
AU2016250843A1 (en) * | 2015-04-24 | 2017-10-12 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
JP2018535969A (en) * | 2015-11-04 | 2018-12-06 | オメロス コーポレーション | Solid state form of PDE10 inhibitor |
-
2011
- 2011-03-10 KR KR1020157000406A patent/KR101713453B1/en active IP Right Grant
- 2011-03-10 ES ES11754087T patent/ES2742195T3/en active Active
- 2011-03-10 AU AU2011224287A patent/AU2011224287B2/en active Active
- 2011-03-10 KR KR1020157000405A patent/KR101713452B1/en active IP Right Grant
- 2011-03-10 US US13/045,162 patent/US8343970B2/en active Active
- 2011-03-10 JP JP2012557252A patent/JP5674828B2/en active Active
- 2011-03-10 RU RU2012143610/04A patent/RU2545456C2/en active
- 2011-03-10 NZ NZ705058A patent/NZ705058A/en unknown
- 2011-03-10 CN CN201510032625.0A patent/CN104710385B/en active Active
- 2011-03-10 BR BR112012022910-9A patent/BR112012022910B1/en active IP Right Grant
- 2011-03-10 CA CA2792844A patent/CA2792844C/en active Active
- 2011-03-10 EP EP11754087.2A patent/EP2544679B1/en active Active
- 2011-03-10 PT PT11754087T patent/PT2544679T/en unknown
- 2011-03-10 MX MX2012010400A patent/MX339950B/en active IP Right Grant
- 2011-03-10 KR KR1020127026545A patent/KR101512548B1/en active IP Right Grant
- 2011-03-10 CN CN201710695057.1A patent/CN107445919A/en not_active Withdrawn
- 2011-03-10 DK DK11754087.2T patent/DK2544679T3/en active
- 2011-03-10 KR KR1020177005754A patent/KR101846136B1/en active IP Right Grant
- 2011-03-10 PL PL11754087T patent/PL2544679T3/en unknown
- 2011-03-10 NZ NZ724645A patent/NZ724645A/en unknown
- 2011-03-10 NZ NZ60196711A patent/NZ601967A/en unknown
- 2011-03-10 WO PCT/US2011/027927 patent/WO2011112828A1/en active Application Filing
- 2011-03-10 CN CN201180012372.0A patent/CN102869355B/en active Active
-
2012
- 2012-09-07 ZA ZA2012/06718A patent/ZA201206718B/en unknown
- 2012-09-11 CL CL2012002506A patent/CL2012002506A1/en unknown
- 2012-09-11 IL IL221906A patent/IL221906B/en active IP Right Grant
- 2012-11-16 US US13/679,818 patent/US8685975B2/en active Active
-
2014
- 2014-02-11 US US14/177,952 patent/US9102643B2/en active Active
- 2014-07-24 JP JP2014150417A patent/JP2014198727A/en active Pending
-
2015
- 2015-01-20 US US14/601,100 patent/US9434707B2/en active Active
-
2016
- 2016-08-04 US US15/229,020 patent/US10106516B2/en active Active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693652A (en) | 1991-09-30 | 1997-12-02 | Eisai Co., Ltd. | Benzimidazoles for ischemic heart conditions |
WO1996000218A1 (en) | 1994-06-24 | 1996-01-04 | Euro-Celtique, S.A. | Compounds for and method of inhibiting phosphodiesterase iv |
US6403805B1 (en) * | 1995-04-06 | 2002-06-11 | Janssen Pharmaceutica N.V. | 1,3-dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatves |
US6177154B1 (en) | 1996-09-17 | 2001-01-23 | Chisso Corporation | Alkoxybenzene derivative, liquid-crystal composition, and liquid-crystal display element |
WO2001041807A2 (en) | 1999-12-10 | 2001-06-14 | Vivus, Inc. | Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
US20060128695A1 (en) | 2002-10-30 | 2006-06-15 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
US7129238B2 (en) | 2002-11-25 | 2006-10-31 | Hoffmann-La Roche Inc. | Mandelic acid derivatives |
EP1568691A1 (en) | 2002-12-06 | 2005-08-31 | Kowa Co., Ltd. | Erythropoietin production accelerator |
US20090221586A1 (en) * | 2005-11-15 | 2009-09-03 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound and pharmaceutical composition |
WO2007073299A1 (en) | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Imidazoles as gaba-b receptor modulators |
US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
WO2008040669A2 (en) | 2006-10-02 | 2008-04-10 | Janssen Pharmaceutica N.V. | Novel intermediates for the preparation of a glyt1 inhibitor |
WO2010017236A1 (en) | 2008-08-05 | 2010-02-11 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
Non-Patent Citations (10)
Title |
---|
FUJISHIGE ET AL.: "Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDElOA", J BIOL CHEM, vol. 274, 1999, pages 18438 - 18445, XP002475766, DOI: doi:10.1074/jbc.274.26.18438 |
GENNARO: "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO. |
LEE, H. ET AL., TETRAHEDRON LETTERS, vol. 45, 2004, pages 1019 |
LOUGHNEY ET AL.: "Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase", GENE, vol. 234, 1999, pages 109 - 117, XP004176895, DOI: doi:10.1016/S0378-1119(99)00171-7 |
LUGNIER, C.: "Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents", PHARMACOL THER., vol. 109, no. 3, March 2006 (2006-03-01), pages 366 - 98, XP025038516, DOI: doi:10.1016/j.pharmthera.2005.07.003 |
SODERLING ET AL.: "Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A", PROC NATL ACAD SCI USA, vol. 96, 1999, pages 7071 - 7076, XP002351820, DOI: doi:10.1073/pnas.96.12.7071 |
SODERLING; BEAVO: "Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions", CURRENT OPINION IN CELL BIOLOGY, vol. 12, 2000, pages 174 - 179, XP001003042, DOI: doi:10.1016/S0955-0674(99)00073-3 |
TANAKA, A. ET AL., J. MED. CHEM., 1998 |
THOMPSON; APPLEMAN, BIOCHEMISTRY, vol. 10, 1971, pages 311 - 316 |
ZAFRANI, Y., TETRAHEDRON, vol. 65, 2009, pages 5278 |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8278327B2 (en) | 2006-11-21 | 2012-10-02 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US9783521B2 (en) | 2008-08-05 | 2017-10-10 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US8685975B2 (en) | 2010-03-12 | 2014-04-01 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US10106516B2 (en) | 2010-03-12 | 2018-10-23 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US9670181B2 (en) | 2011-02-18 | 2017-06-06 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
US8772316B2 (en) | 2011-02-18 | 2014-07-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) |
WO2012112946A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
JP2015521193A (en) * | 2012-05-31 | 2015-07-27 | フェネックス ファーマシューティカルス アーゲー | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators of the orphan nuclear receptor RORγ |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
US9902710B2 (en) | 2013-12-05 | 2018-02-27 | Exonhit Therapeutics, Sa | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
US9650368B2 (en) | 2014-04-28 | 2017-05-16 | Omeros Corporation | Processes and intermediates for the preparation of a PDE10 inhibitor |
US9493447B2 (en) | 2014-04-28 | 2016-11-15 | Omeros Corporation | Optically active PDE10 inhibitor |
US9850238B2 (en) | 2014-04-28 | 2017-12-26 | Omeros Corporation | Optically active PDE10 inhibitor |
US9879002B2 (en) | 2015-04-24 | 2018-01-30 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
EP3285760A4 (en) * | 2015-04-24 | 2018-09-26 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
US9920045B2 (en) | 2015-11-04 | 2018-03-20 | Omeros Corporation | Solid state forms of a PDE10 inhibitor |
CN113272285A (en) * | 2018-09-21 | 2021-08-17 | 爱思开生物制药株式会社 | Oxadiazole-containing compound and pharmaceutical composition containing the same |
EP3854788A4 (en) * | 2018-09-21 | 2022-06-15 | SK Biopharmaceuticals Co., Ltd. | Compound containing oxadiazole, and pharmaceutical composition containing same |
CN113272285B (en) * | 2018-09-21 | 2024-06-07 | 爱思开生物制药株式会社 | Oxadiazole-containing compound and pharmaceutical composition containing same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10106516B2 (en) | PDE10 inhibitors and related compositions and methods | |
JP5966014B2 (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of diseases | |
US8217065B2 (en) | Organic compounds | |
CA2733378C (en) | Pde10 inhibitors and related compositions and methods | |
JP5423675B2 (en) | Azole compounds | |
SK16242002A3 (en) | Triazole derivative and a pharmaceutical composition containing the same | |
WO2010044404A1 (en) | Fused heterocyclic derivative and use thereof for medical purposes | |
JP2019532929A (en) | Compounds and their use as PDE4 activators | |
KR20040081123A (en) | Coumarin derivatives, process for their production and use thereof | |
RU2512547C2 (en) | Derivative, containing condensed ring structure, and its application in medicine | |
WO2019022234A1 (en) | Inflammatory bowel disease therapeutic agent or prophylactic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180012372.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11754087 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7265/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/010400 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012557252 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2792844 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012002506 Country of ref document: CL Ref document number: 221906 Country of ref document: IL Ref document number: 2011224287 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011224287 Country of ref document: AU Date of ref document: 20110310 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127026545 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011754087 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012143610 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012022910 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012022910 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120911 |